[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fll1ZJW5-k4ZW48J10Ak0Uf2E1XH8Hay2c0lesV1isyw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University Hospital, Toulouse",[4],786,false,183,36,1102076,57,595,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Parkinson Disease",23,{"name":18,"count":19},"Obesity",16,{"name":21,"count":22},"Prader-Willi Syndrome",15,{"name":24,"count":25},"Multiple Myeloma",12,{"name":27,"count":25},"Stroke",{"name":29,"count":30},"Alzheimer Disease",11,{"name":32,"count":33},"Pain",8,{"name":35,"count":33},"COVID-19",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03581370","Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia","2025-02","1 hour",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06817200","The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial","2025-05-01","Amantadine (100mg) as add on therapy.",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04282629","Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral Ischemia","2025-07","Milrinone",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04896684","Chronic Intestinal Pathologies Analytical Cohort at TouLouse","2025-09","blood and intestinal biopsy sampling",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06362447","Efficacy of Injectable Gentamicin in Hereditary Ichthyosis","2026-04-01","Gentamicin Injectable Solution",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04751760","Feasibility Study of a New Immunoglobulin E (IgE) Assay Method","2026-04-20","collection of blood and urine",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06432556","Study of Cellular Heterogeneity in Patients With Mastocytosis","2026-06-08","scRNAseq",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04970472","Bio Clinical Collection of Urothelial Carcinoma","2026-07-14","collection of blood, urines, stool and tumor samples",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04970459","Biological Collection for Marfan and Related Syndromes","2026-08-07","collection of samples of blood and urine",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT03534713","Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread","2026-09","Carboplatin",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,124,142,169,197,215,233,251,290,315,341,367,392,418,436,458,476,500,518,536,582,615,648,672,697,719,742,760,786,807,828,851,876,971,1018,1063,1102,1136,1161,1179,1204,1222,1249,1267,1291,1309,1334,1355,1381,1402,1423,1454,1478,1500,1525,1543,1566,1589,1637,1683,1709,1745,1781,1803,1828,1852,1877,1902,1920,1938,1963,1988,2006,2032,2050,2076,2094,2118,2136,2161,2186,2204,2228,2253,2271,2296,2321,2345,2369,2396,2414,2439,2461,2484,2509,2527,2554,2572,2622,2648,2680,2712,2736,2760,2783,2809,2827,2854,2872,2890,2913,2936,2954,2980,2998,3016,3041,3066,3090,3116,3134,3152,3170,3188,3212,3236,3260,3278,3302,3327,3351,3376,3400,3418,3436,3462,3480,3515,3547,3569,3595,3613,3636,3660,3685,3710,3733,3751,3776,3794,3817,3840,3863,3888,3910,3933,3957,3975,4001,4027,4052,4076,4099,4117,4135,4160,4182,4214,4235,4257,4281,4306,4382,4431,4453,4480,4504,4527,4545,4569,4594,4617,4645,4672,4696,4719,4743,4767,4794,4819,4837,4855,4873,4898,4921,4939,4957,4975,4998,5016,5041,5059,5077,5103,5127,5148,5166,5190,5214,5236,5259,5282,5300,5318,5340,5363],{"intervention":96,"totalTrials":97,"cells":98},"a second infusion of ZOL when crosslaps levels reach 300 pg\u002FmL",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":122},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT06767150","StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis","RECRUITING",[92],"2030-10","2025-10-02",200,[119],"Postmenopausal Osteoporosis",[96,121],"a rescue second infusion at month-12",{"trials":123,"activeCount":101},[],{"intervention":121,"totalTrials":97,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":127,"activeCount":101},[],{"trials":129,"activeCount":101},[],{"trials":131,"activeCount":101},[],{"trials":133,"activeCount":101},[],{"trials":135,"activeCount":97,"soonestReadout":115},[136],{"nctId":111,"briefTitle":112,"status":113,"phases":137,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":138,"interventions":139},[92],[119],[96,121],{"trials":141,"activeCount":101},[],{"intervention":143,"totalTrials":97,"cells":144},"Stopping dupilumab",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":167},{"trials":146,"activeCount":101},[],{"trials":148,"activeCount":101},[],{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":97,"soonestReadout":160},[155],{"nctId":156,"briefTitle":157,"status":158,"phases":159,"primaryCompletion":160,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"NCT06818019","Withdrawal of Dupilumab in Severe Asthma","NOT_YET_RECRUITING",[92],"2027-12-31","2029-12-31","2025-04-02",205,[165],"Severe Asthma",[143],{"trials":168,"activeCount":101},[],{"intervention":170,"totalTrials":97,"cells":171},"Baricitinib (LY3009104) 4 mg",{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":195},{"trials":173,"activeCount":101},[],{"trials":175,"activeCount":101},[],{"trials":177,"activeCount":101},[],{"trials":179,"activeCount":101},[],{"trials":181,"activeCount":97,"soonestReadout":186},[182],{"nctId":183,"briefTitle":184,"status":158,"phases":185,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT06687551","JAK Inhibitor Dose TAPering Strategy Study",[92],"2029-04-01","2025-01-01",308,[190],"Rhumatoid Arthisis",[170,192,193,194,170,192,193,194],"filgotinib 200mg\u002Fday","Tofacitinib 5 mg twice daily","Upadacitinib 15 MG",{"trials":196,"activeCount":101},[],{"intervention":192,"totalTrials":97,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":213},{"trials":200,"activeCount":101},[],{"trials":202,"activeCount":101},[],{"trials":204,"activeCount":101},[],{"trials":206,"activeCount":101},[],{"trials":208,"activeCount":97,"soonestReadout":186},[209],{"nctId":183,"briefTitle":184,"status":158,"phases":210,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":211,"interventions":212},[92],[190],[170,192,193,194,170,192,193,194],{"trials":214,"activeCount":101},[],{"intervention":193,"totalTrials":97,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":101},[],{"trials":220,"activeCount":101},[],{"trials":222,"activeCount":101},[],{"trials":224,"activeCount":101},[],{"trials":226,"activeCount":97,"soonestReadout":186},[227],{"nctId":183,"briefTitle":184,"status":158,"phases":228,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":229,"interventions":230},[92],[190],[170,192,193,194,170,192,193,194],{"trials":232,"activeCount":101},[],{"intervention":194,"totalTrials":97,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":249},{"trials":236,"activeCount":101},[],{"trials":238,"activeCount":101},[],{"trials":240,"activeCount":101},[],{"trials":242,"activeCount":101},[],{"trials":244,"activeCount":97,"soonestReadout":186},[245],{"nctId":183,"briefTitle":184,"status":158,"phases":246,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":247,"interventions":248},[92],[190],[170,192,193,194,170,192,193,194],{"trials":250,"activeCount":101},[],{"intervention":252,"totalTrials":253,"cells":254},"Aspirin",2,{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":272,"PHASE4":286,"NA":288},{"trials":256,"activeCount":101},[],{"trials":258,"activeCount":101},[],{"trials":260,"activeCount":101},[261],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT04912505","ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase","COMPLETED",[90],"2024-01-02","2023-01-16",4,[270],"Purpura, Thrombocytopenic",[252],{"trials":273,"activeCount":97,"soonestReadout":278},[274],{"nctId":275,"briefTitle":276,"status":113,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":285},"NCT05625724","Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology",[91],"2028-08","2029-05","2023-08-02",1164,[283,284],"ART","Pre-Eclampsia",[252],{"trials":287,"activeCount":101},[],{"trials":289,"activeCount":101},[],{"intervention":291,"totalTrials":97,"cells":292},"BOTOX",{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":311,"NA":313},{"trials":294,"activeCount":101},[],{"trials":296,"activeCount":101},[],{"trials":298,"activeCount":101},[],{"trials":300,"activeCount":97,"soonestReadout":305},[301],{"nctId":302,"briefTitle":303,"status":158,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":33,"conditions":307,"interventions":310},"NCT05698979","Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease",[91],"2028-02","2027-01-01",[308,309],"Buerger Disease","Raynaud Syndrome",[291],{"trials":312,"activeCount":101},[],{"trials":314,"activeCount":101},[],{"intervention":316,"totalTrials":97,"cells":317},"Avacopan",{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":337,"NA":339},{"trials":319,"activeCount":101},[],{"trials":321,"activeCount":101},[],{"trials":323,"activeCount":101},[],{"trials":325,"activeCount":97,"soonestReadout":330},[326],{"nctId":327,"briefTitle":328,"status":158,"phases":329,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT07373262","Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement",[91],"2030-03-01","2030-07-01","2026-03-01",130,[335],"ANCA-Associated Vasculitis (AAV)",[316],{"trials":338,"activeCount":101},[],{"trials":340,"activeCount":101},[],{"intervention":342,"totalTrials":97,"cells":343},"Amoxi Clavulanate",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":363,"NA":365},{"trials":345,"activeCount":101},[],{"trials":347,"activeCount":101},[],{"trials":349,"activeCount":101},[],{"trials":351,"activeCount":97,"soonestReadout":356},[352],{"nctId":353,"briefTitle":354,"status":158,"phases":355,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT07587450","Efficacy of Non Operative Treatment With Amoxicillin\u002FClavulanic Acid Versus Surgical Treatment in Acute Uncomplicated Appendicitis in Children",[91],"2029-09-01","2034-09-01","2026-09-01",724,[361],"Acute Uncomplicated Appendicitis",[342],{"trials":364,"activeCount":101},[],{"trials":366,"activeCount":101},[],{"intervention":368,"totalTrials":97,"cells":369},"Propranolol Oral Product",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":388,"NA":390},{"trials":371,"activeCount":101},[],{"trials":373,"activeCount":101},[],{"trials":375,"activeCount":101},[],{"trials":377,"activeCount":97,"soonestReadout":382},[378],{"nctId":379,"briefTitle":380,"status":113,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT04985344","Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol",[91],"2027-09","2023-02-01",92,[386],"PTSD",[368],{"trials":389,"activeCount":101},[],{"trials":391,"activeCount":101},[],{"intervention":393,"totalTrials":97,"cells":394},"ultrasound-guided betamethasone infiltration of the meniscal wall",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":414,"NA":416},{"trials":396,"activeCount":101},[],{"trials":398,"activeCount":101},[],{"trials":400,"activeCount":101},[],{"trials":402,"activeCount":97,"soonestReadout":407},[403],{"nctId":404,"briefTitle":405,"status":113,"phases":406,"primaryCompletion":407,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT06527235","Meniscal INfiltration of Corticosteroid Guided With Ultra Sonography",[91],"2028-06-01","2025-03-06",152,[411],"Meniscus Lesion",[393,413],"ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall",{"trials":415,"activeCount":101},[],{"trials":417,"activeCount":101},[],{"intervention":413,"totalTrials":97,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":432,"NA":434},{"trials":421,"activeCount":101},[],{"trials":423,"activeCount":101},[],{"trials":425,"activeCount":101},[],{"trials":427,"activeCount":97,"soonestReadout":407},[428],{"nctId":404,"briefTitle":405,"status":113,"phases":429,"primaryCompletion":407,"completion":407,"start":408,"enrollment":409,"conditions":430,"interventions":431},[91],[411],[393,413],{"trials":433,"activeCount":101},[],{"trials":435,"activeCount":101},[],{"intervention":41,"totalTrials":97,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":454,"NA":456},{"trials":439,"activeCount":101},[],{"trials":441,"activeCount":101},[],{"trials":443,"activeCount":101},[],{"trials":445,"activeCount":97,"soonestReadout":40},[446],{"nctId":38,"briefTitle":39,"status":113,"phases":447,"primaryCompletion":40,"completion":40,"start":448,"enrollment":449,"conditions":450,"interventions":452},[91],"2018-09-20",80,[451],"Ventilator-associated Pneumonia",[41,453],"4 hours",{"trials":455,"activeCount":101},[],{"trials":457,"activeCount":101},[],{"intervention":453,"totalTrials":97,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":472,"NA":474},{"trials":461,"activeCount":101},[],{"trials":463,"activeCount":101},[],{"trials":465,"activeCount":101},[],{"trials":467,"activeCount":97,"soonestReadout":40},[468],{"nctId":38,"briefTitle":39,"status":113,"phases":469,"primaryCompletion":40,"completion":40,"start":448,"enrollment":449,"conditions":470,"interventions":471},[91],[451],[41,453],{"trials":473,"activeCount":101},[],{"trials":475,"activeCount":101},[],{"intervention":86,"totalTrials":97,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":484,"PHASE4":496,"NA":498},{"trials":479,"activeCount":101},[],{"trials":481,"activeCount":101},[],{"trials":483,"activeCount":101},[],{"trials":485,"activeCount":97,"soonestReadout":85},[486],{"nctId":83,"briefTitle":84,"status":113,"phases":487,"primaryCompletion":85,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},[91],"2026-12","2020-07-17",310,[492],"Cervical Cancer TNM Staging Regional Lymph Nodes (N)",[86,494,495],"Paclitaxel","Cisplatin",{"trials":497,"activeCount":101},[],{"trials":499,"activeCount":101},[],{"intervention":494,"totalTrials":97,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":514,"NA":516},{"trials":503,"activeCount":101},[],{"trials":505,"activeCount":101},[],{"trials":507,"activeCount":101},[],{"trials":509,"activeCount":97,"soonestReadout":85},[510],{"nctId":83,"briefTitle":84,"status":113,"phases":511,"primaryCompletion":85,"completion":488,"start":489,"enrollment":490,"conditions":512,"interventions":513},[91],[492],[86,494,495],{"trials":515,"activeCount":101},[],{"trials":517,"activeCount":101},[],{"intervention":495,"totalTrials":97,"cells":519},{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":532,"NA":534},{"trials":521,"activeCount":101},[],{"trials":523,"activeCount":101},[],{"trials":525,"activeCount":101},[],{"trials":527,"activeCount":97,"soonestReadout":85},[528],{"nctId":83,"briefTitle":84,"status":113,"phases":529,"primaryCompletion":85,"completion":488,"start":489,"enrollment":490,"conditions":530,"interventions":531},[91],[492],[86,494,495],{"trials":533,"activeCount":101},[],{"trials":535,"activeCount":101},[],{"intervention":537,"totalTrials":538,"cells":539},"AdMSC",3,{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":541,"activeCount":101},[],{"trials":543,"activeCount":101},[],{"trials":545,"activeCount":538,"soonestReadout":550},[546,556,567],{"nctId":547,"briefTitle":548,"status":113,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT04356755","Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.",[90],"2027-03","2020-09-22",32,[554],"Systemic Sclerosis",[537],{"nctId":557,"briefTitle":558,"status":158,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":566},"NCT07326033","Efficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosis and Handicap in Patients With Systemic sclEroderma",[90],"2028-04-30","2028-07-31","2026-01",50,[565],"Systemic Scleroderma",[537],{"nctId":568,"briefTitle":569,"status":113,"phases":570,"primaryCompletion":382,"completion":382,"start":571,"enrollment":572,"conditions":573,"interventions":575},"NCT06636032","Dose Escalation of Allogeneic Adipose Derived Stroma\u002FStem Cells for the Treatment of Crohn's Fistula",[89,90],"2025-03-12",9,[574],"Crohn Disease",[537],{"trials":577,"activeCount":101},[],{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":101},[],{"intervention":583,"totalTrials":253,"cells":584},"Oxytocin nasal spray",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":600,"PHASE4":611,"NA":613},{"trials":586,"activeCount":101},[],{"trials":588,"activeCount":101},[],{"trials":590,"activeCount":97,"soonestReadout":488},[591],{"nctId":592,"briefTitle":593,"status":158,"phases":594,"primaryCompletion":488,"completion":488,"start":595,"enrollment":596,"conditions":597,"interventions":599},"NCT05864508","Interest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study.",[90],"2023-07",30,[598],"Autism Spectrum Disorder",[583],{"trials":601,"activeCount":101},[602],{"nctId":603,"briefTitle":604,"status":264,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT05298085","Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome",[90,91],"2023-04-11","2022-04-05",25,[21],[583],{"trials":612,"activeCount":101},[],{"trials":614,"activeCount":101},[],{"intervention":616,"totalTrials":253,"cells":617},"Rapamycin",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":619,"activeCount":101},[],{"trials":621,"activeCount":101},[],{"trials":623,"activeCount":97,"soonestReadout":628},[624,632],{"nctId":625,"briefTitle":626,"status":158,"phases":627,"primaryCompletion":628,"completion":628,"start":358,"enrollment":608,"conditions":629,"interventions":631},"NCT06308445","Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis",[90],"2030-09",[630],"Familial Adenomatous Polyposis",[616],{"nctId":633,"briefTitle":634,"status":264,"phases":635,"primaryCompletion":636,"completion":636,"start":637,"enrollment":563,"conditions":638,"interventions":640},"NCT00235560","Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients",[90],"2008-06","2005-06",[639],"Acute Myeloid Leukemia",[641],"rapamycin",{"trials":643,"activeCount":101},[],{"trials":645,"activeCount":101},[],{"trials":647,"activeCount":101},[],{"intervention":649,"totalTrials":97,"cells":650},"a positon emission tomography (PET) exam",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":666,"PHASE4":668,"NA":670},{"trials":652,"activeCount":101},[],{"trials":654,"activeCount":101},[],{"trials":656,"activeCount":97,"soonestReadout":661},[657],{"nctId":658,"briefTitle":659,"status":158,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":665},"NCT07007208","Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk",[90],"2029-01-31","2026-01-01",100,[29],[649],{"trials":667,"activeCount":101},[],{"trials":669,"activeCount":101},[],{"trials":671,"activeCount":101},[],{"intervention":673,"totalTrials":97,"cells":674},"IV Ketamine (0.5 mg\u002Fkg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":676,"activeCount":101},[],{"trials":678,"activeCount":101},[],{"trials":680,"activeCount":97,"soonestReadout":685},[681],{"nctId":682,"briefTitle":683,"status":158,"phases":684,"primaryCompletion":685,"completion":685,"start":358,"enrollment":686,"conditions":687,"interventions":690},"NCT07099534","Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder",[90],"2028-09-30",38,[688,689],"Infusion of Ketamine in Severe Borderline Personality Disorder","Borderline Personality Disorder (BPD)",[673],{"trials":692,"activeCount":101},[],{"trials":694,"activeCount":101},[],{"trials":696,"activeCount":101},[],{"intervention":61,"totalTrials":97,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":700,"activeCount":101},[],{"trials":702,"activeCount":101},[],{"trials":704,"activeCount":97,"soonestReadout":60},[705],{"nctId":58,"briefTitle":59,"status":158,"phases":706,"primaryCompletion":60,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":712},[90],"2027-04-01","2024-09",26,[711],"Ichthyosis",[61],{"trials":714,"activeCount":101},[],{"trials":716,"activeCount":101},[],{"trials":718,"activeCount":101},[],{"intervention":720,"totalTrials":97,"cells":721},"CellREADY® drug product IV dose of 50 millions",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":723,"activeCount":101},[],{"trials":725,"activeCount":101},[],{"trials":727,"activeCount":97,"soonestReadout":732},[728],{"nctId":729,"briefTitle":730,"status":158,"phases":731,"primaryCompletion":732,"completion":732,"start":332,"enrollment":572,"conditions":733,"interventions":734},"NCT07367815","Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease",[89,90],"2029-03-01",[29],[720,735],"CellREADY® drug product IV dose of 100 millions",{"trials":737,"activeCount":101},[],{"trials":739,"activeCount":101},[],{"trials":741,"activeCount":101},[],{"intervention":735,"totalTrials":97,"cells":743},{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":745,"activeCount":101},[],{"trials":747,"activeCount":101},[],{"trials":749,"activeCount":97,"soonestReadout":732},[750],{"nctId":729,"briefTitle":730,"status":158,"phases":751,"primaryCompletion":732,"completion":732,"start":332,"enrollment":572,"conditions":752,"interventions":753},[89,90],[29],[720,735],{"trials":755,"activeCount":101},[],{"trials":757,"activeCount":101},[],{"trials":759,"activeCount":101},[],{"intervention":761,"totalTrials":97,"cells":762},"TEP with 18F-DPA-714",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":764,"activeCount":101},[],{"trials":766,"activeCount":101},[],{"trials":768,"activeCount":97,"soonestReadout":773},[769],{"nctId":770,"briefTitle":771,"status":158,"phases":772,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT07583147","Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.",[90],"2029-09","2029-12","2026-06",117,[778],"Intracerebral Hemorrhage",[761],{"trials":781,"activeCount":101},[],{"trials":783,"activeCount":101},[],{"trials":785,"activeCount":101},[],{"intervention":46,"totalTrials":97,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":789,"activeCount":101},[],{"trials":791,"activeCount":101},[],{"trials":793,"activeCount":97,"soonestReadout":45},[794],{"nctId":43,"briefTitle":44,"status":158,"phases":795,"primaryCompletion":45,"completion":796,"start":45,"enrollment":797,"conditions":798,"interventions":800},[90],"2027-08-31",132,[799],"Parkinson Disease (PD)",[46],{"trials":802,"activeCount":101},[],{"trials":804,"activeCount":101},[],{"trials":806,"activeCount":101},[],{"intervention":51,"totalTrials":97,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":822,"PHASE4":824,"NA":826},{"trials":810,"activeCount":101},[],{"trials":812,"activeCount":101},[],{"trials":814,"activeCount":97,"soonestReadout":50},[815],{"nctId":48,"briefTitle":49,"status":113,"phases":816,"primaryCompletion":50,"completion":50,"start":817,"enrollment":818,"conditions":819,"interventions":821},[90],"2021-07-25",234,[820],"Aneurysmal Subarachnoid Hemorrhage",[51],{"trials":823,"activeCount":101},[],{"trials":825,"activeCount":101},[],{"trials":827,"activeCount":101},[],{"intervention":829,"totalTrials":97,"cells":830},"Acyclovir",{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":832,"activeCount":101},[],{"trials":834,"activeCount":97,"soonestReadout":488},[835],{"nctId":836,"briefTitle":837,"status":113,"phases":838,"primaryCompletion":488,"completion":488,"start":839,"enrollment":840,"conditions":841,"interventions":842},"NCT05589688","Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir",[89],"2024-04-09",20,[18],[829],{"trials":844,"activeCount":101},[],{"trials":846,"activeCount":101},[],{"trials":848,"activeCount":101},[],{"trials":850,"activeCount":101},[],{"intervention":852,"totalTrials":97,"cells":853},"Adipose tissue derived mesenchymal Stroma\u002Fstem Cells transplantation",{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":855,"activeCount":101},[],{"trials":857,"activeCount":97,"soonestReadout":862},[858],{"nctId":859,"briefTitle":860,"status":158,"phases":861,"primaryCompletion":862,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":867},"NCT06795620","Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma\u002FStem Cells (AdMSC) Transplantation in Patients With Critical Limb Ischemia.",[89],"2028-01","2025-01",10,[866],"Critical Limb Ischemia",[852],{"trials":869,"activeCount":101},[],{"trials":871,"activeCount":101},[],{"trials":873,"activeCount":101},[],{"trials":875,"activeCount":101},[],{"intervention":877,"totalTrials":878,"cells":879},"Blood sampling",6,{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":881,"activeCount":101},[],{"trials":883,"activeCount":101},[],{"trials":885,"activeCount":101},[],{"trials":887,"activeCount":101},[],{"trials":889,"activeCount":101},[],{"trials":891,"activeCount":970,"soonestReadout":926},[892,907,922,936,949,961],{"nctId":893,"briefTitle":894,"status":113,"phases":895,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":905},"NCT06387654","Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases",[],"2029-04","2034-04","2024-05-06",800,[901,902,903,904],"Autoimmune Bullous Dermatosis","Dysimmune Dermatological Diseases","Auto-inflammatory Dermatological Diseases","Skin Diseases",[877,906],"Remainders of samples taken as part of the treatment",{"nctId":908,"briefTitle":909,"status":113,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":915,"interventions":921},"NCT05251415","Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases",[],"2027-04-04","2032-04-04","2022-04-04",3000,[916,917,918,919,920],"Lupus Erythematosus","Scleroderma","Myositis","Vasculitis","Inflammatory Bowel Diseases",[877],{"nctId":923,"briefTitle":924,"status":113,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":935},"NCT05039216","Biobank for Inflammatory Chronic Diseases and Osteoporosis",[],"2026-09-02","2031-09-01","2021-09-13",2000,[931,932,933,934],"Rheumatoid Arthritis","Psoriatic Arthritis","Spondyloarthritis","Osteoporosis",[877],{"nctId":937,"briefTitle":938,"status":264,"phases":939,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":944,"interventions":947},"NCT04907565","Impact of Obesity on Post-operative Cognitive Dysfunction: Role of Adipose Tissue",[],"2024-09-30","2025-03-30","2021-09-21",115,[18,945,946],"Cognitive Impairment","Post-Operative Confusion",[877,948],"white adipose tissue sampling",{"nctId":950,"briefTitle":951,"status":952,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":608,"conditions":956,"interventions":960},"NCT05646888","Inflammation, Platelets and Sickle Cell Disease","ACTIVE_NOT_RECRUITING",[],"2026-11-30","2023-01-15",[957,958,959],"Platelet Activation","Thromboinflammation","Sickle Cell Disease",[877],{"nctId":962,"briefTitle":963,"status":113,"phases":964,"primaryCompletion":965,"completion":965,"start":966,"enrollment":840,"conditions":967,"interventions":969},"NCT06408701","Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular Malformations",[],"2034-05-02","2024-11-05",[968],"Eye Abnormalities",[877],5,{"intervention":972,"totalTrials":538,"cells":973},"Blood collection on admission and longitudinally",{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":975,"activeCount":101},[],{"trials":977,"activeCount":101},[],{"trials":979,"activeCount":101},[],{"trials":981,"activeCount":101},[],{"trials":983,"activeCount":101},[],{"trials":985,"activeCount":97,"soonestReadout":1001},[986,997,1008],{"nctId":987,"briefTitle":988,"status":264,"phases":989,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":994,"interventions":995},"NCT04668170","Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management",[],"2021-12-31","2023-05-02","2020-05-05",304,[35],[972,996],"Blood collection on their first consultation and 10 to 14 days later",{"nctId":998,"briefTitle":999,"status":113,"phases":1000,"primaryCompletion":1001,"completion":1002,"start":1003,"enrollment":1004,"conditions":1005,"interventions":1007},"NCT04698421","Collection of Biological Samples From Patients With Rare Neurological Diseases",[],"2030-01-01","2030-09-03","2020-10-12",1000,[1006],"Nervous System Diseases",[972],{"nctId":1009,"briefTitle":1010,"status":264,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1017},"NCT04385108","Predictive Immune Biomarkers for COVID-19 Pathogenesis",[93],"2020-12-31","2021-12-24","2020-03-04",565,[35],[972,996],{"intervention":1019,"totalTrials":538,"cells":1020},"Blood samples",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1022,"activeCount":101},[],{"trials":1024,"activeCount":101},[],{"trials":1026,"activeCount":101},[],{"trials":1028,"activeCount":101},[],{"trials":1030,"activeCount":101},[],{"trials":1032,"activeCount":97,"soonestReadout":488},[1033,1044,1054],{"nctId":1034,"briefTitle":1035,"status":264,"phases":1036,"primaryCompletion":1037,"completion":1038,"start":1039,"enrollment":1040,"conditions":1041,"interventions":1043},"NCT03482115","Brain Network Disruptions Related to Traumatic Coma",[93],"2021-11-07","2022-02-07","2018-03-07",59,[1042],"Traumatic Coma",[1019],{"nctId":1045,"briefTitle":1046,"status":113,"phases":1047,"primaryCompletion":488,"completion":488,"start":1048,"enrollment":1049,"conditions":1050,"interventions":1053},"NCT05306912","Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules",[93],"2022-04-08",60,[1051,1052],"Lung Cancer","Lung; Node",[1019],{"nctId":1055,"briefTitle":1056,"status":264,"phases":1057,"primaryCompletion":1058,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1062},"NCT04397822","COVID-19 : Study of INFLAmmasome and PLAtelets Functions",[],"2022-05-25","2020-04-16",61,[35],[1019],{"intervention":1064,"totalTrials":253,"cells":1065},"Azacitidine",{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1072,"PHASE4":1088,"NA":1090},{"trials":1067,"activeCount":101},[],{"trials":1069,"activeCount":101},[],{"trials":1071,"activeCount":101},[],{"trials":1073,"activeCount":101},[1074],{"nctId":1075,"briefTitle":1076,"status":1077,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1084},"NCT03765541","Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia","TERMINATED",[91],"2024-05-31","2020-01-13",73,[1083],"Relapsed or Refractory Acute Myeloid Leukemia",[1085,1086,1087,1064],"Dexamethasone","Amsacrine","Cytarabine",{"trials":1089,"activeCount":101},[],{"trials":1091,"activeCount":97,"soonestReadout":1096},[1092],{"nctId":1093,"briefTitle":1094,"status":952,"phases":1095,"primaryCompletion":1096,"completion":1096,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1100},"NCT03284593","Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition",[],"2030-12","2014-12",199,[639],[1101,1064],"intensive chemotherapy",{"intervention":1103,"totalTrials":253,"cells":1104},"Collection of blood and urine",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":101},[],{"trials":1108,"activeCount":101},[],{"trials":1110,"activeCount":101},[],{"trials":1112,"activeCount":101},[],{"trials":1114,"activeCount":101},[],{"trials":1116,"activeCount":97,"soonestReadout":65},[1117,1129],{"nctId":1118,"briefTitle":1119,"status":264,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1126},"NCT04453917","Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy",[93],"2024-07-12","2021-02-23",22,[1125],"Progressive Multifocal Leukoencephalopathy",[1103,1127,1128],"Spinal tap","Neurological evaluation",{"nctId":63,"briefTitle":64,"status":113,"phases":1130,"primaryCompletion":65,"completion":65,"start":1131,"enrollment":1132,"conditions":1133,"interventions":1135},[],"2021-04-20",1376,[1134],"Allergy and Immunology",[66],{"intervention":1137,"totalTrials":97,"cells":1138},"Blood sample for the determination of antihypertensives or their metabolites.",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":101},[],{"trials":1146,"activeCount":101},[],{"trials":1148,"activeCount":101},[],{"trials":1150,"activeCount":97,"soonestReadout":1155},[1151],{"nctId":1152,"briefTitle":1153,"status":113,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1160},"NCT05156385","Sexual Dysfunction in Hypertensive Women",[93],"2027-07-07","2022-06-27",348,[1159],"Hypertension",[1137],{"intervention":1101,"totalTrials":97,"cells":1162},{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1164,"activeCount":101},[],{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":101},[],{"trials":1170,"activeCount":101},[],{"trials":1172,"activeCount":101},[],{"trials":1174,"activeCount":97,"soonestReadout":1096},[1175],{"nctId":1093,"briefTitle":1094,"status":952,"phases":1176,"primaryCompletion":1096,"completion":1096,"start":1097,"enrollment":1098,"conditions":1177,"interventions":1178},[],[639],[1101,1064],{"intervention":1180,"totalTrials":97,"cells":1181},"Peripheral immunological assessment on venous blood",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1183,"activeCount":101},[],{"trials":1185,"activeCount":101},[],{"trials":1187,"activeCount":101},[],{"trials":1189,"activeCount":101},[],{"trials":1191,"activeCount":101},[],{"trials":1193,"activeCount":97,"soonestReadout":1198},[1194],{"nctId":1195,"briefTitle":1196,"status":113,"phases":1197,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":449,"conditions":1200,"interventions":1202},"NCT05209776","Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy",[93],"2027-02","2022-02-01",[1201],"Arrhythmogenic Right Ventricular Dysplasia",[1180,1203],"Immunological assessment carried out on intracardiac material",{"intervention":1203,"totalTrials":97,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1214,"NA":1216},{"trials":1207,"activeCount":101},[],{"trials":1209,"activeCount":101},[],{"trials":1211,"activeCount":101},[],{"trials":1213,"activeCount":101},[],{"trials":1215,"activeCount":101},[],{"trials":1217,"activeCount":97,"soonestReadout":1198},[1218],{"nctId":1195,"briefTitle":1196,"status":113,"phases":1219,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":449,"conditions":1220,"interventions":1221},[93],[1201],[1180,1203],{"intervention":1223,"totalTrials":97,"cells":1224},"Take 1 ml of blood",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1226,"activeCount":101},[],{"trials":1228,"activeCount":101},[],{"trials":1230,"activeCount":101},[],{"trials":1232,"activeCount":101},[],{"trials":1234,"activeCount":101},[],{"trials":1236,"activeCount":97,"soonestReadout":1241},[1237],{"nctId":1238,"briefTitle":1239,"status":113,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":117,"conditions":1243,"interventions":1247},"NCT07075601","Non-interventional Study Exploring the Composition of the Valvular Microbiota of Patients Undergoing Cardiac Surgery",[93],"2029-08-31","2025-11-19",[1244,1245,1246],"Valvulopathy","Cardiac Surgery","Microbiota",[1223,1248],"DNA sequencing",{"intervention":1248,"totalTrials":97,"cells":1250},{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1257,"PHASE4":1259,"NA":1261},{"trials":1252,"activeCount":101},[],{"trials":1254,"activeCount":101},[],{"trials":1256,"activeCount":101},[],{"trials":1258,"activeCount":101},[],{"trials":1260,"activeCount":101},[],{"trials":1262,"activeCount":97,"soonestReadout":1241},[1263],{"nctId":1238,"briefTitle":1239,"status":113,"phases":1264,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":117,"conditions":1265,"interventions":1266},[93],[1244,1245,1246],[1223,1248],{"intervention":1268,"totalTrials":97,"cells":1269},"Extra blood sampling, Non-invasive or leftover samples or medical waste",{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":101},[],{"trials":1275,"activeCount":101},[],{"trials":1277,"activeCount":101},[],{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":97,"soonestReadout":1286},[1282],{"nctId":1283,"briefTitle":1284,"status":113,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":914,"conditions":1288,"interventions":1290},"NCT06054854","Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease)",[],"2033-10-01","2024-06-13",[1289,1051],"Lung Nodule",[1268],{"intervention":906,"totalTrials":97,"cells":1292},{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1299,"PHASE4":1301,"NA":1303},{"trials":1294,"activeCount":101},[],{"trials":1296,"activeCount":101},[],{"trials":1298,"activeCount":101},[],{"trials":1300,"activeCount":101},[],{"trials":1302,"activeCount":101},[],{"trials":1304,"activeCount":97,"soonestReadout":896},[1305],{"nctId":893,"briefTitle":894,"status":113,"phases":1306,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":1307,"interventions":1308},[],[901,902,903,904],[877,906],{"intervention":1310,"totalTrials":97,"cells":1311},"blood and urine sampling",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1320,"NA":1322},{"trials":1313,"activeCount":101},[],{"trials":1315,"activeCount":101},[],{"trials":1317,"activeCount":101},[],{"trials":1319,"activeCount":101},[],{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":97,"soonestReadout":1328},[1324],{"nctId":1325,"briefTitle":1326,"status":113,"phases":1327,"primaryCompletion":1328,"completion":1329,"start":1330,"enrollment":663,"conditions":1331,"interventions":1333},"NCT05202210","Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome",[],"2027-01-26","2032-01-26","2022-01-26",[1332],"Noonan Syndrome",[1310],{"intervention":56,"totalTrials":97,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1337,"activeCount":101},[],{"trials":1339,"activeCount":101},[],{"trials":1341,"activeCount":101},[],{"trials":1343,"activeCount":101},[],{"trials":1345,"activeCount":101},[],{"trials":1347,"activeCount":97,"soonestReadout":55},[1348],{"nctId":53,"briefTitle":54,"status":113,"phases":1349,"primaryCompletion":55,"completion":55,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1354},[],"2021-04-29",300,[920,1353],"Colon Cancer",[56],{"intervention":1356,"totalTrials":97,"cells":1357},"additional blood samples",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1359,"activeCount":101},[],{"trials":1361,"activeCount":101},[],{"trials":1363,"activeCount":101},[],{"trials":1365,"activeCount":101},[],{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":97,"soonestReadout":1374},[1370],{"nctId":1371,"briefTitle":1372,"status":113,"phases":1373,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1380},"NCT04809506","Identification of New Biomarkers for the Prediction of Cardiovascular Events",[],"2030-02-03","2034-02-03","2021-02-04",1500,[1379],"Cardiovascular Diseases",[1356],{"intervention":81,"totalTrials":97,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1384,"activeCount":101},[],{"trials":1386,"activeCount":101},[],{"trials":1388,"activeCount":101},[],{"trials":1390,"activeCount":101},[],{"trials":1392,"activeCount":101},[],{"trials":1394,"activeCount":97,"soonestReadout":80},[1395],{"nctId":78,"briefTitle":79,"status":113,"phases":1396,"primaryCompletion":80,"completion":1397,"start":1398,"enrollment":1351,"conditions":1399,"interventions":1401},[],"2031-08-07","2022-01-24",[1400],"Marfan Syndrome",[81],{"intervention":71,"totalTrials":97,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1405,"activeCount":101},[],{"trials":1407,"activeCount":101},[],{"trials":1409,"activeCount":101},[],{"trials":1411,"activeCount":101},[],{"trials":1413,"activeCount":101},[],{"trials":1415,"activeCount":97,"soonestReadout":70},[1416],{"nctId":68,"briefTitle":69,"status":158,"phases":1417,"primaryCompletion":70,"completion":1418,"start":1419,"enrollment":709,"conditions":1420,"interventions":1422},[93],"2026-06-15","2024-06-01",[1421],"Mastocytosis",[71],{"intervention":1424,"totalTrials":97,"cells":1425},"Biological samples collection",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1427,"activeCount":101},[],{"trials":1429,"activeCount":101},[],{"trials":1431,"activeCount":101},[],{"trials":1433,"activeCount":101},[],{"trials":1435,"activeCount":101},[],{"trials":1437,"activeCount":97,"soonestReadout":1442},[1438],{"nctId":1439,"briefTitle":1440,"status":113,"phases":1441,"primaryCompletion":1442,"completion":1443,"start":1444,"enrollment":1445,"conditions":1446,"interventions":1453},"NCT05318196","Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases",[],"2027-09-01","2032-09-01","2022-09-05",5000,[1447,1448,1449,1450,1451,1452],"Acute Kidney Injury","Chronic Kidney Diseases","Solid-organ Transplantation","Cancer","Metabolic Disease","Immune Diseases",[1424],{"intervention":1455,"totalTrials":97,"cells":1456},"CSF sample",{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1458,"activeCount":101},[],{"trials":1460,"activeCount":101},[],{"trials":1462,"activeCount":101},[],{"trials":1464,"activeCount":101},[],{"trials":1466,"activeCount":101},[],{"trials":1468,"activeCount":97,"soonestReadout":1198},[1469],{"nctId":1470,"briefTitle":1471,"status":113,"phases":1472,"primaryCompletion":1198,"completion":1198,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1477},"NCT06482463","Diagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis",[93],"2025-02-12",185,[1476],"Nosocomial Infection",[1455],{"intervention":76,"totalTrials":97,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1481,"activeCount":101},[],{"trials":1483,"activeCount":101},[],{"trials":1485,"activeCount":101},[],{"trials":1487,"activeCount":101},[],{"trials":1489,"activeCount":101},[],{"trials":1491,"activeCount":97,"soonestReadout":75},[1492],{"nctId":73,"briefTitle":74,"status":113,"phases":1493,"primaryCompletion":75,"completion":1494,"start":1495,"enrollment":1004,"conditions":1496,"interventions":1499},[],"2031-07-14","2021-11-16",[1497,1498],"Urothelial Carcinoma","Bladder Cancer",[76],{"intervention":1501,"totalTrials":97,"cells":1502},"Transfusion algorithm based on Quantra®",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1513},{"trials":1504,"activeCount":101},[],{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":101},[],{"trials":1514,"activeCount":97,"soonestReadout":550},[1515],{"nctId":1516,"briefTitle":1517,"status":113,"phases":1518,"primaryCompletion":550,"completion":550,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1523},"NCT06749405","Assessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation",[93],"2025-03-08",56,[1522],"Liver Transplantation",[1501,1524],"Conventional transfusion algorithm",{"intervention":1524,"totalTrials":97,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1535,"NA":1537},{"trials":1528,"activeCount":101},[],{"trials":1530,"activeCount":101},[],{"trials":1532,"activeCount":101},[],{"trials":1534,"activeCount":101},[],{"trials":1536,"activeCount":101},[],{"trials":1538,"activeCount":97,"soonestReadout":550},[1539],{"nctId":1516,"briefTitle":1517,"status":113,"phases":1540,"primaryCompletion":550,"completion":550,"start":1519,"enrollment":1520,"conditions":1541,"interventions":1542},[93],[1522],[1501,1524],{"intervention":1544,"totalTrials":97,"cells":1545},"semen, blood and urine tests",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1547,"activeCount":101},[],{"trials":1549,"activeCount":101},[],{"trials":1551,"activeCount":101},[],{"trials":1553,"activeCount":101},[],{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":97,"soonestReadout":1198},[1558],{"nctId":1559,"briefTitle":1560,"status":158,"phases":1561,"primaryCompletion":1198,"completion":1198,"start":1562,"enrollment":22,"conditions":1563,"interventions":1565},"NCT06983548","Chikungunya Virus Detection in Semen",[93],"2025-05",[1564],"Chikungunya Virus Infection",[1544],{"intervention":1567,"totalTrials":97,"cells":1568},"Blood and bone marrow sampling",{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1575,"PHASE4":1577,"NA":1579},{"trials":1570,"activeCount":101},[],{"trials":1572,"activeCount":101},[],{"trials":1574,"activeCount":101},[],{"trials":1576,"activeCount":101},[],{"trials":1578,"activeCount":101},[],{"trials":1580,"activeCount":97,"soonestReadout":1585},[1581],{"nctId":1582,"briefTitle":1583,"status":158,"phases":1584,"primaryCompletion":1585,"completion":1585,"start":50,"enrollment":840,"conditions":1586,"interventions":1588},"NCT07026851","Pilot Study to Establish a Repertoire of Megakaryocyte Markers, Quantifiable by Spectral Flow Cytometry, in Bone Marrow and Circulating in Patients Undergoing Cardiac Surgery for Bypass Grafting",[],"2027-07",[1587],"Cardiac Surgery for Bypass Grafting",[1567],{"intervention":1590,"totalTrials":538,"cells":1591},"Morphine",{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1598,"PHASE4":1611,"NA":1635},{"trials":1593,"activeCount":101},[],{"trials":1595,"activeCount":101},[],{"trials":1597,"activeCount":101},[],{"trials":1599,"activeCount":101},[1600],{"nctId":1601,"briefTitle":1602,"status":264,"phases":1603,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1609},"NCT00656773","A Randomized, Double-blind Comparison of Morphine and Sufentanil for Prehospital Traumatic Severe Acute Pain",[91],"2008-09","2008-01",108,[1608],"Acute Pain",[1610,1590],"Sufentanil",{"trials":1612,"activeCount":101},[1613,1624],{"nctId":1614,"briefTitle":1615,"status":264,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1620,"interventions":1622},"NCT02198378","Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.",[92],"2017-01","2014-11",680,[1621],"Acute Coronary Syndrome",[1623,1590],"MEOPA and paracetamol",{"nctId":1625,"briefTitle":1626,"status":264,"phases":1627,"primaryCompletion":1628,"completion":1628,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1633},"NCT00237731","Pre-hospital Morphine Titration : Comparison of 0,05 Versus 0,1 mg\u002Fkg",[92],"2006-03","2005-09",106,[1632],"Severe, Acute Pain in a Pre-hospital Setting",[1634,1634],"morphine",{"trials":1636,"activeCount":101},[],{"intervention":1638,"totalTrials":538,"cells":1639},"Fluoxetine",{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1669,"PHASE4":1671,"NA":1681},{"trials":1641,"activeCount":101},[],{"trials":1643,"activeCount":101},[],{"trials":1645,"activeCount":101},[1646,1658],{"nctId":1647,"briefTitle":1648,"status":264,"phases":1649,"primaryCompletion":1650,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1656},"NCT01146548","Fluoxetine in Multiple System Atrophy Patients",[90],"2011-06","2011-09","2008-05",87,[1655],"Multiple System Atrophy",[1657],"FLUOXETINE",{"nctId":1659,"briefTitle":1660,"status":264,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":663,"conditions":1664,"interventions":1667},"NCT00657163","Fluoxetine on Motor Rehabilitation After Ischemic Stroke",[90],"2010-12","2005-03",[1665,1666],"Ischemic Stroke","Motor Impairment",[1668],"fluoxetine",{"trials":1670,"activeCount":101},[],{"trials":1672,"activeCount":101},[1673],{"nctId":1674,"briefTitle":1675,"status":264,"phases":1676,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":608,"conditions":1679,"interventions":1680},"NCT02767999","Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke",[92],"2022-01-31","2017-02-27",[27],[1638],{"trials":1682,"activeCount":101},[],{"intervention":1610,"totalTrials":253,"cells":1684},{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1691,"PHASE4":1697,"NA":1707},{"trials":1686,"activeCount":101},[],{"trials":1688,"activeCount":101},[],{"trials":1690,"activeCount":101},[],{"trials":1692,"activeCount":101},[1693],{"nctId":1601,"briefTitle":1602,"status":264,"phases":1694,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":1606,"conditions":1695,"interventions":1696},[91],[1608],[1610,1590],{"trials":1698,"activeCount":101},[1699],{"nctId":1700,"briefTitle":1701,"status":264,"phases":1702,"primaryCompletion":1703,"completion":1703,"start":1704,"enrollment":608,"conditions":1705,"interventions":1706},"NCT01356732","Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients",[92],"2010-10","2010-01",[32],[1610],{"trials":1708,"activeCount":101},[],{"intervention":1710,"totalTrials":253,"cells":1711},"Remifentanil",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1743},{"trials":1713,"activeCount":101},[],{"trials":1715,"activeCount":101},[],{"trials":1717,"activeCount":101},[],{"trials":1719,"activeCount":101},[],{"trials":1721,"activeCount":101},[1722,1733],{"nctId":1723,"briefTitle":1724,"status":264,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":1049,"conditions":1728,"interventions":1731},"NCT05026125","Quality Assessment of Orotracheal Intubation Without Neuromuscular Blocking Agents in Obese Patients",[92],"2023-08-11","2022-01-13",[18,1729,1730],"Bariatric Surgery Candidate","Intubation Complication",[1710,1732],"Remifentanil Injection plus 30%",{"nctId":1734,"briefTitle":1735,"status":264,"phases":1736,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1740,"interventions":1742},"NCT02206022","Remifentanil And Local Anesthesia Compared With Local Anesthesia For The Insertion Of Central Venous Catheters",[92],"2017-12","2014-08",90,[1741],"Local Anesthesia",[1710],{"trials":1744,"activeCount":101},[],{"intervention":1746,"totalTrials":253,"cells":1747},"Premixed 50% nitrous oxide and oxygen",{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1754,"PHASE4":1768,"NA":1779},{"trials":1749,"activeCount":101},[],{"trials":1751,"activeCount":101},[],{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":101},[1756],{"nctId":1757,"briefTitle":1758,"status":1077,"phases":1759,"primaryCompletion":1760,"completion":1761,"start":1762,"enrollment":1763,"conditions":1764,"interventions":1766},"NCT01990404","Efficacy of Premixed Nitrous Oxide and Oxygen in Elderly Patient With Out-of-hospital Severe Acute Pain",[90,91],"2015-12","2016-06","2013-07",43,[1765],"Pain Acute",[1746,1767],"Medical Air",{"trials":1769,"activeCount":101},[1770],{"nctId":1771,"briefTitle":1772,"status":264,"phases":1773,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":1049,"conditions":1776,"interventions":1777},"NCT01356745","Efficacy of Premixed Nitrous Oxide and Oxygen in Patient With Out-of-hospital Moderate Acute Pain",[92],"2011-05","2010-02",[1608],[1746,1778],"medical air",{"trials":1780,"activeCount":101},[],{"intervention":1767,"totalTrials":253,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1789,"PHASE4":1795,"NA":1801},{"trials":1784,"activeCount":101},[],{"trials":1786,"activeCount":101},[],{"trials":1788,"activeCount":101},[],{"trials":1790,"activeCount":101},[1791],{"nctId":1757,"briefTitle":1758,"status":1077,"phases":1792,"primaryCompletion":1760,"completion":1761,"start":1762,"enrollment":1763,"conditions":1793,"interventions":1794},[90,91],[1765],[1746,1767],{"trials":1796,"activeCount":101},[1797],{"nctId":1771,"briefTitle":1772,"status":264,"phases":1798,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":1049,"conditions":1799,"interventions":1800},[92],[1608],[1746,1778],{"trials":1802,"activeCount":101},[],{"intervention":1804,"totalTrials":97,"cells":1805},"GlucoCorticoid",{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1812,"PHASE4":1814,"NA":1826},{"trials":1807,"activeCount":101},[],{"trials":1809,"activeCount":101},[],{"trials":1811,"activeCount":101},[],{"trials":1813,"activeCount":101},[],{"trials":1815,"activeCount":101},[1816],{"nctId":1817,"briefTitle":1818,"status":264,"phases":1819,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":1822,"conditions":1823,"interventions":1825},"NCT02997605","Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients",[92],"2022-01-27","2017-01-31",102,[1824],"RheumatoId Arthritis",[1804],{"trials":1827,"activeCount":101},[],{"intervention":1829,"totalTrials":97,"cells":1830},"oestradiol",{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1835,"PHASE3":1837,"PHASE4":1839,"NA":1850},{"trials":1832,"activeCount":101},[],{"trials":1834,"activeCount":101},[],{"trials":1836,"activeCount":101},[],{"trials":1838,"activeCount":101},[],{"trials":1840,"activeCount":101},[1841],{"nctId":1842,"briefTitle":1843,"status":264,"phases":1844,"primaryCompletion":1704,"completion":1704,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1849},"NCT00701337","Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route",[92],"2006-09",40,[1848],"Postmenopausal",[1829,1829],{"trials":1851,"activeCount":101},[],{"intervention":1853,"totalTrials":97,"cells":1854},"piperacillin\u002Ftazobactam",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1875},{"trials":1856,"activeCount":101},[],{"trials":1858,"activeCount":101},[],{"trials":1860,"activeCount":101},[],{"trials":1862,"activeCount":101},[],{"trials":1864,"activeCount":101},[1865],{"nctId":1866,"briefTitle":1867,"status":264,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":636,"enrollment":864,"conditions":1870,"interventions":1874},"NCT00703144","Pharmacokinetics of Piperacillin\u002FTazobactam in Patients Treated by Continuous Renal Replacement Therapy",[92],"2012-08",[1871,1872,1873],"Diffusive and Convective Clearance","Body Clearance","Piperacillin Tazocilline Concentrations (Cmin)",[1853],{"trials":1876,"activeCount":101},[],{"intervention":1878,"totalTrials":97,"cells":1879},"tacrolimus",{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1886,"PHASE4":1888,"NA":1900},{"trials":1881,"activeCount":101},[],{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[],{"trials":1889,"activeCount":101},[1890],{"nctId":1891,"briefTitle":1892,"status":264,"phases":1893,"primaryCompletion":1704,"completion":1894,"start":1895,"enrollment":663,"conditions":1896,"interventions":1897},"NCT00538265","Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation",[92],"2011-01","2005-05",[1522],[1878,1898,1899],"tacrolimus, ATG","ATG+mycophénolate mofétil+tacrolimus",{"trials":1901,"activeCount":101},[],{"intervention":1898,"totalTrials":97,"cells":1903},{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1910,"PHASE4":1912,"NA":1918},{"trials":1905,"activeCount":101},[],{"trials":1907,"activeCount":101},[],{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[1914],{"nctId":1891,"briefTitle":1892,"status":264,"phases":1915,"primaryCompletion":1704,"completion":1894,"start":1895,"enrollment":663,"conditions":1916,"interventions":1917},[92],[1522],[1878,1898,1899],{"trials":1919,"activeCount":101},[],{"intervention":1899,"totalTrials":97,"cells":1921},{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1936},{"trials":1923,"activeCount":101},[],{"trials":1925,"activeCount":101},[],{"trials":1927,"activeCount":101},[],{"trials":1929,"activeCount":101},[],{"trials":1931,"activeCount":101},[1932],{"nctId":1891,"briefTitle":1892,"status":264,"phases":1933,"primaryCompletion":1704,"completion":1894,"start":1895,"enrollment":663,"conditions":1934,"interventions":1935},[92],[1522],[1878,1898,1899],{"trials":1937,"activeCount":101},[],{"intervention":1939,"totalTrials":97,"cells":1940},"Detemir insulin, Aspart insulin, Metformin",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1961},{"trials":1942,"activeCount":101},[],{"trials":1944,"activeCount":101},[],{"trials":1946,"activeCount":101},[],{"trials":1948,"activeCount":101},[],{"trials":1950,"activeCount":101},[1951],{"nctId":1952,"briefTitle":1953,"status":264,"phases":1954,"primaryCompletion":1955,"completion":1955,"start":1956,"enrollment":1957,"conditions":1958,"interventions":1960},"NCT00942318","Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes",[92],"2013-02","2009-03",52,[1959],"Type 2 Diabetes Mellitus",[1939],{"trials":1962,"activeCount":101},[],{"intervention":1964,"totalTrials":97,"cells":1965},"valsartan\u002Fsacubitril 100 mg",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1986},{"trials":1967,"activeCount":101},[],{"trials":1969,"activeCount":101},[],{"trials":1971,"activeCount":101},[],{"trials":1973,"activeCount":101},[],{"trials":1975,"activeCount":101},[1976],{"nctId":1977,"briefTitle":1978,"status":1077,"phases":1979,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":268,"conditions":1982,"interventions":1984},"NCT02787798","Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure",[92],"2018-01","2016-10",[1983],"Heart Failure",[1964,1985],"valsartan\u002Fsacubitril 200 mg",{"trials":1987,"activeCount":101},[],{"intervention":1985,"totalTrials":97,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2004},{"trials":1991,"activeCount":101},[],{"trials":1993,"activeCount":101},[],{"trials":1995,"activeCount":101},[],{"trials":1997,"activeCount":101},[],{"trials":1999,"activeCount":101},[2000],{"nctId":1977,"briefTitle":1978,"status":1077,"phases":2001,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":268,"conditions":2002,"interventions":2003},[92],[1983],[1964,1985],{"trials":2005,"activeCount":101},[],{"intervention":2007,"totalTrials":97,"cells":2008},"Remifentanyl - sufentanil placebo",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2030},{"trials":2010,"activeCount":101},[],{"trials":2012,"activeCount":101},[],{"trials":2014,"activeCount":101},[],{"trials":2016,"activeCount":101},[],{"trials":2018,"activeCount":101},[2019],{"nctId":2020,"briefTitle":2021,"status":264,"phases":2022,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":2025,"conditions":2026,"interventions":2028},"NCT01910285","Remifentanil Versus Sufentanil for Intubation Condition Without Myorelaxant",[92],"2015-09","2013-06",70,[2027],"Anaesthetic Induction",[2007,2029],"Sufentanil - remifentanyl placebo",{"trials":2031,"activeCount":101},[],{"intervention":2029,"totalTrials":97,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2042,"NA":2048},{"trials":2035,"activeCount":101},[],{"trials":2037,"activeCount":101},[],{"trials":2039,"activeCount":101},[],{"trials":2041,"activeCount":101},[],{"trials":2043,"activeCount":101},[2044],{"nctId":2020,"briefTitle":2021,"status":264,"phases":2045,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":2025,"conditions":2046,"interventions":2047},[92],[2027],[2007,2029],{"trials":2049,"activeCount":101},[],{"intervention":2051,"totalTrials":97,"cells":2052},"Normal bolus",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2059,"PHASE4":2061,"NA":2074},{"trials":2054,"activeCount":101},[],{"trials":2056,"activeCount":101},[],{"trials":2058,"activeCount":101},[],{"trials":2060,"activeCount":101},[],{"trials":2062,"activeCount":101},[2063],{"nctId":2064,"briefTitle":2065,"status":264,"phases":2066,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":2069,"conditions":2070,"interventions":2072},"NCT02229097","Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients",[92],"2016-11","2014-10",17,[2071],"Type 1 Diabetes",[2051,2073],"Coordinated bolus",{"trials":2075,"activeCount":101},[],{"intervention":2073,"totalTrials":97,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2092},{"trials":2079,"activeCount":101},[],{"trials":2081,"activeCount":101},[],{"trials":2083,"activeCount":101},[],{"trials":2085,"activeCount":101},[],{"trials":2087,"activeCount":101},[2088],{"nctId":2064,"briefTitle":2065,"status":264,"phases":2089,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":2069,"conditions":2090,"interventions":2091},[92],[2071],[2051,2073],{"trials":2093,"activeCount":101},[],{"intervention":2095,"totalTrials":97,"cells":2096},"Simulect",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2116},{"trials":2098,"activeCount":101},[],{"trials":2100,"activeCount":101},[],{"trials":2102,"activeCount":101},[],{"trials":2104,"activeCount":101},[],{"trials":2106,"activeCount":101},[2107],{"nctId":2108,"briefTitle":2109,"status":264,"phases":2110,"primaryCompletion":1617,"completion":1617,"start":2111,"enrollment":1049,"conditions":2112,"interventions":2114},"NCT02377193","Simulect Versus ATG in Sensitized Renal Transplant Patient",[92],"2013-09",[2113],"Renal Transplant Rejection",[2095,2115],"ATG Fresenius",{"trials":2117,"activeCount":101},[],{"intervention":2115,"totalTrials":97,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2134},{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":101},[],{"trials":2127,"activeCount":101},[],{"trials":2129,"activeCount":101},[2130],{"nctId":2108,"briefTitle":2109,"status":264,"phases":2131,"primaryCompletion":1617,"completion":1617,"start":2111,"enrollment":1049,"conditions":2132,"interventions":2133},[92],[2113],[2095,2115],{"trials":2135,"activeCount":101},[],{"intervention":2137,"totalTrials":97,"cells":2138},"Natalizumab",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2159},{"trials":2140,"activeCount":101},[],{"trials":2142,"activeCount":101},[],{"trials":2144,"activeCount":101},[],{"trials":2146,"activeCount":101},[],{"trials":2148,"activeCount":101},[2149],{"nctId":2150,"briefTitle":2151,"status":264,"phases":2152,"primaryCompletion":2153,"completion":2154,"start":2155,"enrollment":1351,"conditions":2156,"interventions":2158},"NCT00942214","Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment",[92],"2011-02","2011-03","2009-06",[2157],"Multiple Sclerosis",[2137],{"trials":2160,"activeCount":101},[],{"intervention":2162,"totalTrials":97,"cells":2163},"MRI",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2184},{"trials":2165,"activeCount":101},[],{"trials":2167,"activeCount":101},[],{"trials":2169,"activeCount":101},[],{"trials":2171,"activeCount":101},[],{"trials":2173,"activeCount":101},[2174],{"nctId":2175,"briefTitle":2176,"status":264,"phases":2177,"primaryCompletion":2178,"completion":2179,"start":2180,"enrollment":1049,"conditions":2181,"interventions":2183},"NCT03689361","Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.",[92],"2020-10-11","2020-12-11","2018-12-22",[2182],"Migraine Aura",[2162],{"trials":2185,"activeCount":101},[],{"intervention":1732,"totalTrials":97,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2202},{"trials":2189,"activeCount":101},[],{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":101},[],{"trials":2197,"activeCount":101},[2198],{"nctId":1723,"briefTitle":1724,"status":264,"phases":2199,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":1049,"conditions":2200,"interventions":2201},[92],[18,1729,1730],[1710,1732],{"trials":2203,"activeCount":101},[],{"intervention":2205,"totalTrials":97,"cells":2206},"Atarax",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2226},{"trials":2208,"activeCount":101},[],{"trials":2210,"activeCount":101},[],{"trials":2212,"activeCount":101},[],{"trials":2214,"activeCount":101},[],{"trials":2216,"activeCount":101},[2217],{"nctId":2218,"briefTitle":2219,"status":264,"phases":2220,"primaryCompletion":2111,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2225},"NCT01151696","Pain and Anxiety Management of Traumatic Emergency in a Pre-hospital Setting",[92],"2014-01","2010-05",140,[32],[2205],{"trials":2227,"activeCount":101},[],{"intervention":2229,"totalTrials":97,"cells":2230},"standard treatment",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2251},{"trials":2232,"activeCount":101},[],{"trials":2234,"activeCount":101},[],{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[2241],{"nctId":2242,"briefTitle":2243,"status":264,"phases":2244,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":2247,"conditions":2248,"interventions":2250},"NCT00439075","OUT-OF-HOSPITAL CPAP STUDY",[92],"2008-04","2006-10",124,[2249],"Acute Cardiogenic Pulmonary Edema",[2229],{"trials":2252,"activeCount":101},[],{"intervention":1623,"totalTrials":97,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2269},{"trials":2256,"activeCount":101},[],{"trials":2258,"activeCount":101},[],{"trials":2260,"activeCount":101},[],{"trials":2262,"activeCount":101},[],{"trials":2264,"activeCount":101},[2265],{"nctId":1614,"briefTitle":1615,"status":264,"phases":2266,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":2267,"interventions":2268},[92],[1621],[1623,1590],{"trials":2270,"activeCount":101},[],{"intervention":2272,"totalTrials":97,"cells":2273},"Levofloxacin",{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2280,"PHASE4":2282,"NA":2294},{"trials":2275,"activeCount":101},[],{"trials":2277,"activeCount":101},[],{"trials":2279,"activeCount":101},[],{"trials":2281,"activeCount":101},[],{"trials":2283,"activeCount":101},[2284],{"nctId":2285,"briefTitle":2286,"status":264,"phases":2287,"primaryCompletion":2288,"completion":2288,"start":2289,"enrollment":1957,"conditions":2290,"interventions":2293},"NCT02018081","Pharmacokinetics of Levofloxacin in Intensive Care Unit",[92],"2014-09","2012-03",[2291,2292],"Intensive Care Unit Syndrome","Community-acquired Pneumonia",[2272],{"trials":2295,"activeCount":101},[],{"intervention":2297,"totalTrials":97,"cells":2298},"Anticoagulant",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2319},{"trials":2300,"activeCount":101},[],{"trials":2302,"activeCount":101},[],{"trials":2304,"activeCount":101},[],{"trials":2306,"activeCount":101},[],{"trials":2308,"activeCount":101},[2309],{"nctId":2310,"briefTitle":2311,"status":264,"phases":2312,"primaryCompletion":2313,"completion":2313,"start":2314,"enrollment":2315,"conditions":2316,"interventions":2318},"NCT00966290","Anticoagulant Clinics and Vitamin K Antagonists",[92],"2006-12","2003-02",1006,[2317],"Blood Coagulation Disorders",[2297,2297],{"trials":2320,"activeCount":101},[],{"intervention":2322,"totalTrials":97,"cells":2323},"Linezolid",{"EARLY_PHASE1":2324,"PHASE1":2326,"PHASE2":2328,"PHASE3":2330,"PHASE4":2332,"NA":2343},{"trials":2325,"activeCount":101},[],{"trials":2327,"activeCount":101},[],{"trials":2329,"activeCount":101},[],{"trials":2331,"activeCount":101},[],{"trials":2333,"activeCount":101},[2334],{"nctId":2335,"briefTitle":2336,"status":264,"phases":2337,"primaryCompletion":2338,"completion":2338,"start":2339,"enrollment":1049,"conditions":2340,"interventions":2342},"NCT01200654","Population Pharmacokinetics of Linezolid",[92],"2010-08","2007-11",[2341],"Methicillin-Resistant Staphylococcus AureuS",[2322],{"trials":2344,"activeCount":101},[],{"intervention":2346,"totalTrials":97,"cells":2347},"Blood and milk samples",{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2367},{"trials":2349,"activeCount":101},[],{"trials":2351,"activeCount":101},[],{"trials":2353,"activeCount":101},[],{"trials":2355,"activeCount":101},[],{"trials":2357,"activeCount":101},[2358],{"nctId":2359,"briefTitle":2360,"status":264,"phases":2361,"primaryCompletion":2362,"completion":2362,"start":2363,"enrollment":608,"conditions":2364,"interventions":2366},"NCT05051787","Evaluation of Amoxicillin Diffusion in Breast Milk According to a Population Pharmacokinetic Approach (CONCEPTION-AMOX)",[92],"2023-07-12","2022-06-23",[2365],"Breast Feeding, Exclusive",[2346],{"trials":2368,"activeCount":101},[],{"intervention":2370,"totalTrials":97,"cells":2371},"botulinum A toxin",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2380,"NA":2394},{"trials":2373,"activeCount":101},[],{"trials":2375,"activeCount":101},[],{"trials":2377,"activeCount":101},[],{"trials":2379,"activeCount":101},[],{"trials":2381,"activeCount":101},[2382],{"nctId":2383,"briefTitle":2384,"status":264,"phases":2385,"primaryCompletion":2386,"completion":2387,"start":2388,"enrollment":2389,"conditions":2390,"interventions":2392},"NCT02462317","Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment",[92],"2019-12-09","2020-12-09","2015-04",184,[2391],"Muscle Spasticity",[2370,2393],"Baclofen",{"trials":2395,"activeCount":101},[],{"intervention":2393,"totalTrials":97,"cells":2397},{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2402,"PHASE3":2404,"PHASE4":2406,"NA":2412},{"trials":2399,"activeCount":101},[],{"trials":2401,"activeCount":101},[],{"trials":2403,"activeCount":101},[],{"trials":2405,"activeCount":101},[],{"trials":2407,"activeCount":101},[2408],{"nctId":2383,"briefTitle":2384,"status":264,"phases":2409,"primaryCompletion":2386,"completion":2387,"start":2388,"enrollment":2389,"conditions":2410,"interventions":2411},[92],[2391],[2370,2393],{"trials":2413,"activeCount":101},[],{"intervention":2415,"totalTrials":97,"cells":2416},"Growth hormone",{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2437},{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":101},[],{"trials":2422,"activeCount":101},[],{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":101},[2427],{"nctId":2428,"briefTitle":2429,"status":264,"phases":2430,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":2433,"conditions":2434,"interventions":2436},"NCT01298180","Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?",[92],"2013-05","2009-01",111,[21,2435],"Growth Hormone Deficiency",[2415],{"trials":2438,"activeCount":101},[],{"intervention":2440,"totalTrials":97,"cells":2441},"mantadix",{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2448,"PHASE4":2450,"NA":2459},{"trials":2443,"activeCount":101},[],{"trials":2445,"activeCount":101},[],{"trials":2447,"activeCount":101},[],{"trials":2449,"activeCount":101},[],{"trials":2451,"activeCount":101},[2452],{"nctId":2453,"briefTitle":2454,"status":264,"phases":2455,"primaryCompletion":1894,"completion":1894,"start":2339,"enrollment":449,"conditions":2456,"interventions":2458},"NCT00632762","Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)",[92],[2457],"Parkinson's Disease",[2440],{"trials":2460,"activeCount":101},[],{"intervention":2462,"totalTrials":97,"cells":2463},"lidocaine",{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2482},{"trials":2465,"activeCount":101},[],{"trials":2467,"activeCount":101},[],{"trials":2469,"activeCount":101},[],{"trials":2471,"activeCount":101},[],{"trials":2473,"activeCount":101},[2474],{"nctId":2475,"briefTitle":2476,"status":264,"phases":2477,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":663,"conditions":2480,"interventions":2481},"NCT03453723","Pain Prevention During Propofol Infusion in Pediatric: Hypnoanalgesia of the Hand Versus Lidocaine.",[92],"2019-06-19","2018-04-18",[32],[2462],{"trials":2483,"activeCount":101},[],{"intervention":2485,"totalTrials":97,"cells":2486},"Rituximab 375",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2495,"NA":2507},{"trials":2488,"activeCount":101},[],{"trials":2490,"activeCount":101},[],{"trials":2492,"activeCount":101},[],{"trials":2494,"activeCount":101},[],{"trials":2496,"activeCount":101},[2497],{"nctId":2498,"briefTitle":2499,"status":264,"phases":2500,"primaryCompletion":2501,"completion":1704,"start":1604,"enrollment":840,"conditions":2502,"interventions":2505},"NCT00820469","Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab",[92],"2009-11",[2503,2504],"Renal Transplant","Autoimmune Diseases",[2485,2506],"rituximab 1000",{"trials":2508,"activeCount":101},[],{"intervention":2506,"totalTrials":97,"cells":2510},{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2525},{"trials":2512,"activeCount":101},[],{"trials":2514,"activeCount":101},[],{"trials":2516,"activeCount":101},[],{"trials":2518,"activeCount":101},[],{"trials":2520,"activeCount":101},[2521],{"nctId":2498,"briefTitle":2499,"status":264,"phases":2522,"primaryCompletion":2501,"completion":1704,"start":1604,"enrollment":840,"conditions":2523,"interventions":2524},[92],[2503,2504],[2485,2506],{"trials":2526,"activeCount":101},[],{"intervention":2528,"totalTrials":97,"cells":2529},"ticagrelor",{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2536,"PHASE4":2538,"NA":2552},{"trials":2531,"activeCount":101},[],{"trials":2533,"activeCount":101},[],{"trials":2535,"activeCount":101},[],{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[2540],{"nctId":2541,"briefTitle":2542,"status":264,"phases":2543,"primaryCompletion":2544,"completion":2545,"start":2546,"enrollment":2547,"conditions":2548,"interventions":2550},"NCT02505399","TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement",[92],"2018-05-24","2018-05-30","2015-11",180,[2549],"Atherosclerosis",[2528,2551],"clopidogrel",{"trials":2553,"activeCount":101},[],{"intervention":2551,"totalTrials":97,"cells":2555},{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2570},{"trials":2557,"activeCount":101},[],{"trials":2559,"activeCount":101},[],{"trials":2561,"activeCount":101},[],{"trials":2563,"activeCount":101},[],{"trials":2565,"activeCount":101},[2566],{"nctId":2541,"briefTitle":2542,"status":264,"phases":2567,"primaryCompletion":2544,"completion":2545,"start":2546,"enrollment":2547,"conditions":2568,"interventions":2569},[92],[2549],[2528,2551],{"trials":2571,"activeCount":101},[],{"intervention":2573,"totalTrials":538,"cells":2574},"Lenalidomide",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2604,"PHASE4":2618,"NA":2620},{"trials":2576,"activeCount":101},[],{"trials":2578,"activeCount":101},[],{"trials":2580,"activeCount":101},[2581,2594],{"nctId":2582,"briefTitle":2583,"status":2584,"phases":2585,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":2589,"conditions":2590,"interventions":2591},"NCT03669445","Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma","UNKNOWN",[90],"2024-03","2024-12","2018-12-31",45,[24],[2592,2573,1085,2593],"Ixazomib","Daratumumab",{"nctId":2595,"briefTitle":2596,"status":1077,"phases":2597,"primaryCompletion":2598,"completion":2599,"start":2600,"enrollment":2601,"conditions":2602,"interventions":2603},"NCT02897830","Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma",[90],"2018-11","2020-08-31","2016-08-05",46,[24],[2592,2573,1085],{"trials":2605,"activeCount":101},[2606],{"nctId":2607,"briefTitle":2608,"status":264,"phases":2609,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":2613,"conditions":2614,"interventions":2616},"NCT00430365","Maintenance Therapy Using Lenalidomide in Myeloma",[91],"2017-09","2018-09","2006-06",614,[2615],"Myeloma",[2617],"lenalidomide",{"trials":2619,"activeCount":101},[],{"trials":2621,"activeCount":101},[],{"intervention":1085,"totalTrials":538,"cells":2623},{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2638,"PHASE4":2644,"NA":2646},{"trials":2625,"activeCount":101},[],{"trials":2627,"activeCount":101},[],{"trials":2629,"activeCount":101},[2630,2634],{"nctId":2582,"briefTitle":2583,"status":2584,"phases":2631,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":2589,"conditions":2632,"interventions":2633},[90],[24],[2592,2573,1085,2593],{"nctId":2595,"briefTitle":2596,"status":1077,"phases":2635,"primaryCompletion":2598,"completion":2599,"start":2600,"enrollment":2601,"conditions":2636,"interventions":2637},[90],[24],[2592,2573,1085],{"trials":2639,"activeCount":101},[2640],{"nctId":1075,"briefTitle":1076,"status":1077,"phases":2641,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":2642,"interventions":2643},[91],[1083],[1085,1086,1087,1064],{"trials":2645,"activeCount":101},[],{"trials":2647,"activeCount":101},[],{"intervention":2649,"totalTrials":253,"cells":2650},"prednisone",{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2665,"PHASE4":2676,"NA":2678},{"trials":2652,"activeCount":101},[],{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[2657],{"nctId":2658,"briefTitle":2659,"status":1077,"phases":2660,"primaryCompletion":2023,"completion":1760,"start":1650,"enrollment":2661,"conditions":2662,"interventions":2664},"NCT01452100","Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)",[90],39,[2663],"Cholesterol Embolism Systemic",[2649],{"trials":2666,"activeCount":101},[2667],{"nctId":2668,"briefTitle":2669,"status":264,"phases":2670,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":663,"conditions":2673,"interventions":2675},"NCT02565680","Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency",[90,91],"2014-02","2012-02",[2674],"Acute Urticaria",[2649],{"trials":2677,"activeCount":101},[],{"trials":2679,"activeCount":101},[],{"intervention":2681,"totalTrials":253,"cells":2682},"Lenalidomide, Bortezomib",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2698,"PHASE4":2708,"NA":2710},{"trials":2684,"activeCount":101},[],{"trials":2686,"activeCount":101},[],{"trials":2688,"activeCount":101},[2689],{"nctId":2690,"briefTitle":2691,"status":264,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":2695,"conditions":2696,"interventions":2697},"NCT01206205","Frontline Therapy in de Novo Multiple Myeloma Patients Under 65",[90],"2012-10","2009-08",31,[24],[2681],{"trials":2699,"activeCount":101},[2700],{"nctId":2701,"briefTitle":2702,"status":264,"phases":2703,"primaryCompletion":2704,"completion":2704,"start":1703,"enrollment":2705,"conditions":2706,"interventions":2707},"NCT01191060","Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years",[91],"2018-11-30",700,[2615],[2681,2681],{"trials":2709,"activeCount":101},[],{"trials":2711,"activeCount":101},[],{"intervention":2713,"totalTrials":97,"cells":2714},"L-Threo DOPS",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2732,"NA":2734},{"trials":2716,"activeCount":101},[],{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":101},[],{"trials":2722,"activeCount":101},[2723],{"nctId":2724,"briefTitle":2725,"status":264,"phases":2726,"primaryCompletion":2727,"completion":2727,"start":2728,"enrollment":2729,"conditions":2730,"interventions":2731},"NCT02071459","Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA",[90,91],"2019-10-28","2014-01-21",107,[1655],[2713],{"trials":2733,"activeCount":101},[],{"trials":2735,"activeCount":101},[],{"intervention":2737,"totalTrials":97,"cells":2738},"Eculizumab",{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2745,"PHASE4":2756,"NA":2758},{"trials":2740,"activeCount":101},[],{"trials":2742,"activeCount":101},[],{"trials":2744,"activeCount":101},[],{"trials":2746,"activeCount":101},[2747],{"nctId":2748,"briefTitle":2749,"status":264,"phases":2750,"primaryCompletion":2751,"completion":2751,"start":2752,"enrollment":663,"conditions":2753,"interventions":2755},"NCT02205541","Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU",[91],"2018-06","2015-06",[2754],"Hemolytic Uremic Syndrome of Childhood",[2737],{"trials":2757,"activeCount":101},[],{"trials":2759,"activeCount":101},[],{"intervention":2761,"totalTrials":97,"cells":2762},"Follow-up study of the treated cohort",{"EARLY_PHASE1":2763,"PHASE1":2765,"PHASE2":2767,"PHASE3":2769,"PHASE4":2779,"NA":2781},{"trials":2764,"activeCount":101},[],{"trials":2766,"activeCount":101},[],{"trials":2768,"activeCount":101},[],{"trials":2770,"activeCount":101},[2771],{"nctId":2772,"briefTitle":2773,"status":2584,"phases":2774,"primaryCompletion":2775,"completion":2775,"start":2776,"enrollment":449,"conditions":2777,"interventions":2778},"NCT05032326","Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial",[91],"2025-04-01","2021-09-07",[21],[2761],{"trials":2780,"activeCount":101},[],{"trials":2782,"activeCount":101},[],{"intervention":2784,"totalTrials":97,"cells":2785},"ECC",{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2792,"PHASE4":2805,"NA":2807},{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[],{"trials":2791,"activeCount":101},[],{"trials":2793,"activeCount":101},[2794],{"nctId":2795,"briefTitle":2796,"status":264,"phases":2797,"primaryCompletion":2798,"completion":2798,"start":637,"enrollment":2799,"conditions":2800,"interventions":2803},"NCT00374036","Metastatic Gastric Cancer FFCD 03-07",[91],"2009-12",416,[2801,2802],"Stomach Cancer","Neoplasm Metastasis",[2784,2804],"FOLFIRI",{"trials":2806,"activeCount":101},[],{"trials":2808,"activeCount":101},[],{"intervention":2804,"totalTrials":97,"cells":2810},{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2817,"PHASE4":2823,"NA":2825},{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":101},[],{"trials":2816,"activeCount":101},[],{"trials":2818,"activeCount":101},[2819],{"nctId":2795,"briefTitle":2796,"status":264,"phases":2820,"primaryCompletion":2798,"completion":2798,"start":637,"enrollment":2799,"conditions":2821,"interventions":2822},[91],[2801,2802],[2784,2804],{"trials":2824,"activeCount":101},[],{"trials":2826,"activeCount":101},[],{"intervention":2828,"totalTrials":97,"cells":2829},"PR Oxycodone",{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2836,"PHASE4":2850,"NA":2852},{"trials":2831,"activeCount":101},[],{"trials":2833,"activeCount":101},[],{"trials":2835,"activeCount":101},[],{"trials":2837,"activeCount":101},[2838],{"nctId":2839,"briefTitle":2840,"status":264,"phases":2841,"primaryCompletion":2842,"completion":2842,"start":2843,"enrollment":2844,"conditions":2845,"interventions":2846},"NCT02601586","Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease",[90,91],"2020-11","2016-09",67,[15],[2828,2847,2848,2849],"Levodopa","Oxycodone Placebo","Levodopa placebo",{"trials":2851,"activeCount":101},[],{"trials":2853,"activeCount":101},[],{"intervention":2848,"totalTrials":97,"cells":2855},{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2860,"PHASE3":2862,"PHASE4":2868,"NA":2870},{"trials":2857,"activeCount":101},[],{"trials":2859,"activeCount":101},[],{"trials":2861,"activeCount":101},[],{"trials":2863,"activeCount":101},[2864],{"nctId":2839,"briefTitle":2840,"status":264,"phases":2865,"primaryCompletion":2842,"completion":2842,"start":2843,"enrollment":2844,"conditions":2866,"interventions":2867},[90,91],[15],[2828,2847,2848,2849],{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[],{"intervention":2849,"totalTrials":97,"cells":2873},{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2878,"PHASE3":2880,"PHASE4":2886,"NA":2888},{"trials":2875,"activeCount":101},[],{"trials":2877,"activeCount":101},[],{"trials":2879,"activeCount":101},[],{"trials":2881,"activeCount":101},[2882],{"nctId":2839,"briefTitle":2840,"status":264,"phases":2883,"primaryCompletion":2842,"completion":2842,"start":2843,"enrollment":2844,"conditions":2884,"interventions":2885},[90,91],[15],[2828,2847,2848,2849],{"trials":2887,"activeCount":101},[],{"trials":2889,"activeCount":101},[],{"intervention":2891,"totalTrials":97,"cells":2892},"Hydroxychloroquine",{"EARLY_PHASE1":2893,"PHASE1":2895,"PHASE2":2897,"PHASE3":2899,"PHASE4":2909,"NA":2911},{"trials":2894,"activeCount":101},[],{"trials":2896,"activeCount":101},[],{"trials":2898,"activeCount":101},[],{"trials":2900,"activeCount":101},[2901],{"nctId":2902,"briefTitle":2903,"status":2584,"phases":2904,"primaryCompletion":2905,"completion":2905,"start":2906,"enrollment":596,"conditions":2907,"interventions":2908},"NCT05084872","Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients",[90,91],"2024-01","2021-10",[1421],[2891],{"trials":2910,"activeCount":101},[],{"trials":2912,"activeCount":101},[],{"intervention":2914,"totalTrials":97,"cells":2915},"Bortezomib-Melphalan",{"EARLY_PHASE1":2916,"PHASE1":2918,"PHASE2":2920,"PHASE3":2922,"PHASE4":2932,"NA":2934},{"trials":2917,"activeCount":101},[],{"trials":2919,"activeCount":101},[],{"trials":2921,"activeCount":101},[],{"trials":2923,"activeCount":101},[2924],{"nctId":2925,"briefTitle":2926,"status":264,"phases":2927,"primaryCompletion":2588,"completion":2588,"start":2928,"enrollment":1351,"conditions":2929,"interventions":2930},"NCT02197221","Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma",[91],"2015-01",[24],[2914,2931],"Melphalan",{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[],{"intervention":2931,"totalTrials":97,"cells":2937},{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2944,"PHASE4":2950,"NA":2952},{"trials":2939,"activeCount":101},[],{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"trials":2945,"activeCount":101},[2946],{"nctId":2925,"briefTitle":2926,"status":264,"phases":2947,"primaryCompletion":2588,"completion":2588,"start":2928,"enrollment":1351,"conditions":2948,"interventions":2949},[91],[24],[2914,2931],{"trials":2951,"activeCount":101},[],{"trials":2953,"activeCount":101},[],{"intervention":2955,"totalTrials":97,"cells":2956},"11.25mg GnRH agonist",{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2961,"PHASE3":2963,"PHASE4":2976,"NA":2978},{"trials":2958,"activeCount":101},[],{"trials":2960,"activeCount":101},[],{"trials":2962,"activeCount":101},[],{"trials":2964,"activeCount":101},[2965],{"nctId":2966,"briefTitle":2967,"status":2968,"phases":2969,"primaryCompletion":863,"completion":863,"start":2970,"enrollment":101,"conditions":2971,"interventions":2973},"NCT03940807","Impact of Ultra-long Versus Long Down-regulation Protocol on IVF\u002FICSI in Adenomyosis","WITHDRAWN",[91],"2022-04-29",[2972],"Adenomyosis",[2955,2974,2975],"0.1 mg GnRH agonist","25 µg transdermal oestradiol",{"trials":2977,"activeCount":101},[],{"trials":2979,"activeCount":101},[],{"intervention":2974,"totalTrials":97,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2988,"PHASE4":2994,"NA":2996},{"trials":2983,"activeCount":101},[],{"trials":2985,"activeCount":101},[],{"trials":2987,"activeCount":101},[],{"trials":2989,"activeCount":101},[2990],{"nctId":2966,"briefTitle":2967,"status":2968,"phases":2991,"primaryCompletion":863,"completion":863,"start":2970,"enrollment":101,"conditions":2992,"interventions":2993},[91],[2972],[2955,2974,2975],{"trials":2995,"activeCount":101},[],{"trials":2997,"activeCount":101},[],{"intervention":2975,"totalTrials":97,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3006,"PHASE4":3012,"NA":3014},{"trials":3001,"activeCount":101},[],{"trials":3003,"activeCount":101},[],{"trials":3005,"activeCount":101},[],{"trials":3007,"activeCount":101},[3008],{"nctId":2966,"briefTitle":2967,"status":2968,"phases":3009,"primaryCompletion":863,"completion":863,"start":2970,"enrollment":101,"conditions":3010,"interventions":3011},[91],[2972],[2955,2974,2975],{"trials":3013,"activeCount":101},[],{"trials":3015,"activeCount":101},[],{"intervention":3017,"totalTrials":97,"cells":3018},"potassium iodide",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3025,"PHASE4":3037,"NA":3039},{"trials":3020,"activeCount":101},[],{"trials":3022,"activeCount":101},[],{"trials":3024,"activeCount":101},[],{"trials":3026,"activeCount":101},[3027],{"nctId":3028,"briefTitle":3029,"status":1077,"phases":3030,"primaryCompletion":3031,"completion":3032,"start":2313,"enrollment":3033,"conditions":3034,"interventions":3036},"NCT00379535","Preventing Lack of Iodine During Pregnancy",[91],"2008-12","2010-06",374,[3035],"Pregnancy",[3017],{"trials":3038,"activeCount":101},[],{"trials":3040,"activeCount":101},[],{"intervention":3042,"totalTrials":97,"cells":3043},"gentamicin",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3050,"PHASE4":3062,"NA":3064},{"trials":3045,"activeCount":101},[],{"trials":3047,"activeCount":101},[],{"trials":3049,"activeCount":101},[],{"trials":3051,"activeCount":101},[3052],{"nctId":3053,"briefTitle":3054,"status":264,"phases":3055,"primaryCompletion":3056,"completion":3056,"start":3057,"enrollment":3058,"conditions":3059,"interventions":3061},"NCT03132116","Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis",[91],"2025-08-21","2017-05-31",75,[3060],"Cat-Scratch Disease",[3042],{"trials":3063,"activeCount":101},[],{"trials":3065,"activeCount":101},[],{"intervention":3067,"totalTrials":97,"cells":3068},"OT",{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3075,"PHASE4":3086,"NA":3088},{"trials":3070,"activeCount":101},[],{"trials":3072,"activeCount":101},[],{"trials":3074,"activeCount":101},[],{"trials":3076,"activeCount":101},[3077],{"nctId":3078,"briefTitle":3079,"status":264,"phases":3080,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":1957,"conditions":3084,"interventions":3085},"NCT04283578","Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome",[91],"2021-10-16","2022-03-14","2020-03-10",[21],[3067],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[],{"intervention":3091,"totalTrials":97,"cells":3092},"duloxetine",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3112,"NA":3114},{"trials":3094,"activeCount":101},[],{"trials":3096,"activeCount":101},[],{"trials":3098,"activeCount":101},[],{"trials":3100,"activeCount":101},[3101],{"nctId":3102,"briefTitle":3103,"status":264,"phases":3104,"primaryCompletion":1760,"completion":1760,"start":1774,"enrollment":3105,"conditions":3106,"interventions":3107},"NCT01504178","Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease",[91],28,[2457],[3091,3108,3109,3110,3111],"injection of apomorphine","injection of placebo of apomorphine","L-Dopa","injection of placebo of L-Dopa",{"trials":3113,"activeCount":101},[],{"trials":3115,"activeCount":101},[],{"intervention":3108,"totalTrials":97,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3130,"NA":3132},{"trials":3119,"activeCount":101},[],{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":101},[],{"trials":3125,"activeCount":101},[3126],{"nctId":3102,"briefTitle":3103,"status":264,"phases":3127,"primaryCompletion":1760,"completion":1760,"start":1774,"enrollment":3105,"conditions":3128,"interventions":3129},[91],[2457],[3091,3108,3109,3110,3111],{"trials":3131,"activeCount":101},[],{"trials":3133,"activeCount":101},[],{"intervention":3109,"totalTrials":97,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3148,"NA":3150},{"trials":3137,"activeCount":101},[],{"trials":3139,"activeCount":101},[],{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":101},[3144],{"nctId":3102,"briefTitle":3103,"status":264,"phases":3145,"primaryCompletion":1760,"completion":1760,"start":1774,"enrollment":3105,"conditions":3146,"interventions":3147},[91],[2457],[3091,3108,3109,3110,3111],{"trials":3149,"activeCount":101},[],{"trials":3151,"activeCount":101},[],{"intervention":3110,"totalTrials":97,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3166,"NA":3168},{"trials":3155,"activeCount":101},[],{"trials":3157,"activeCount":101},[],{"trials":3159,"activeCount":101},[],{"trials":3161,"activeCount":101},[3162],{"nctId":3102,"briefTitle":3103,"status":264,"phases":3163,"primaryCompletion":1760,"completion":1760,"start":1774,"enrollment":3105,"conditions":3164,"interventions":3165},[91],[2457],[3091,3108,3109,3110,3111],{"trials":3167,"activeCount":101},[],{"trials":3169,"activeCount":101},[],{"intervention":3111,"totalTrials":97,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3178,"PHASE4":3184,"NA":3186},{"trials":3173,"activeCount":101},[],{"trials":3175,"activeCount":101},[],{"trials":3177,"activeCount":101},[],{"trials":3179,"activeCount":101},[3180],{"nctId":3102,"briefTitle":3103,"status":264,"phases":3181,"primaryCompletion":1760,"completion":1760,"start":1774,"enrollment":3105,"conditions":3182,"interventions":3183},[91],[2457],[3091,3108,3109,3110,3111],{"trials":3185,"activeCount":101},[],{"trials":3187,"activeCount":101},[],{"intervention":3189,"totalTrials":97,"cells":3190},"Omega-3 treatment",{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3197,"PHASE4":3208,"NA":3210},{"trials":3192,"activeCount":101},[],{"trials":3194,"activeCount":101},[],{"trials":3196,"activeCount":101},[],{"trials":3198,"activeCount":101},[3199],{"nctId":3200,"briefTitle":3201,"status":264,"phases":3202,"primaryCompletion":3203,"completion":3203,"start":3204,"enrollment":3205,"conditions":3206,"interventions":3207},"NCT03691519","Prevention of Cognitive Decline in Older Adults With Low Dha\u002FEpa Index in Red Blood Cells",[91],"2020-03-31","2018-04-17",774,[29],[3189],{"trials":3209,"activeCount":101},[],{"trials":3211,"activeCount":101},[],{"intervention":3213,"totalTrials":97,"cells":3214},"hydroxychloroquine\u002Fplacebo",{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3219,"PHASE3":3221,"PHASE4":3232,"NA":3234},{"trials":3216,"activeCount":101},[],{"trials":3218,"activeCount":101},[],{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[3223],{"nctId":3224,"briefTitle":3225,"status":264,"phases":3226,"primaryCompletion":3227,"completion":2313,"start":3228,"enrollment":3058,"conditions":3229,"interventions":3231},"NCT00430807","Hydroxychloroquine in Giant Cell Arteritis",[91],"2005-01","2002-01",[3230],"Giant Cell Arteritis",[3213],{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[],{"intervention":3237,"totalTrials":97,"cells":3238},"Thalidomide",{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3243,"PHASE3":3245,"PHASE4":3256,"NA":3258},{"trials":3240,"activeCount":101},[],{"trials":3242,"activeCount":101},[],{"trials":3244,"activeCount":101},[],{"trials":3246,"activeCount":101},[3247],{"nctId":3248,"briefTitle":3249,"status":264,"phases":3250,"primaryCompletion":3251,"completion":2798,"start":3252,"enrollment":899,"conditions":3253,"interventions":3254},"NCT00222053","IFM 99-02 Thalidomide in Myeloma",[91],"2009-09","2000-04",[24],[3237,3255],"Biphosphonates",{"trials":3257,"activeCount":101},[],{"trials":3259,"activeCount":101},[],{"intervention":3255,"totalTrials":97,"cells":3261},{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3266,"PHASE3":3268,"PHASE4":3274,"NA":3276},{"trials":3263,"activeCount":101},[],{"trials":3265,"activeCount":101},[],{"trials":3267,"activeCount":101},[],{"trials":3269,"activeCount":101},[3270],{"nctId":3248,"briefTitle":3249,"status":264,"phases":3271,"primaryCompletion":3251,"completion":2798,"start":3252,"enrollment":899,"conditions":3272,"interventions":3273},[91],[24],[3237,3255],{"trials":3275,"activeCount":101},[],{"trials":3277,"activeCount":101},[],{"intervention":3279,"totalTrials":97,"cells":3280},"Simvastatin",{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3287,"PHASE4":3298,"NA":3300},{"trials":3282,"activeCount":101},[],{"trials":3284,"activeCount":101},[],{"trials":3286,"activeCount":101},[],{"trials":3288,"activeCount":101},[3289],{"nctId":3290,"briefTitle":3291,"status":264,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":3294,"enrollment":3295,"conditions":3296,"interventions":3297},"NCT02713945","Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome",[91],"2023-03-03","2017-01-25",53,[1332],[3279],{"trials":3299,"activeCount":101},[],{"trials":3301,"activeCount":101},[],{"intervention":3303,"totalTrials":97,"cells":3304},"Botulinic toxin",{"EARLY_PHASE1":3305,"PHASE1":3307,"PHASE2":3309,"PHASE3":3311,"PHASE4":3323,"NA":3325},{"trials":3306,"activeCount":101},[],{"trials":3308,"activeCount":101},[],{"trials":3310,"activeCount":101},[],{"trials":3312,"activeCount":101},[3313],{"nctId":3314,"briefTitle":3315,"status":2584,"phases":3316,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":608,"conditions":3320,"interventions":3322},"NCT03453632","Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex",[90,91],"2023-09","2023-12","2018-06-14",[3321],"Epidermolysis Bullosa Simplex",[3303],{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"intervention":3328,"totalTrials":97,"cells":3329},"Rifaximin",{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3334,"PHASE3":3336,"PHASE4":3347,"NA":3349},{"trials":3331,"activeCount":101},[],{"trials":3333,"activeCount":101},[],{"trials":3335,"activeCount":101},[],{"trials":3337,"activeCount":101},[3338],{"nctId":3339,"briefTitle":3340,"status":264,"phases":3341,"primaryCompletion":3342,"completion":3342,"start":2111,"enrollment":3343,"conditions":3344,"interventions":3346},"NCT02016196","Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS",[91],"2017-07",211,[3345],"Cirrhosis",[3328],{"trials":3348,"activeCount":101},[],{"trials":3350,"activeCount":101},[],{"intervention":3352,"totalTrials":97,"cells":3353},"Oxytocin (OXT) continuous",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3360,"PHASE4":3372,"NA":3374},{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":101},[],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[3362],{"nctId":3363,"briefTitle":3364,"status":264,"phases":3365,"primaryCompletion":3366,"completion":3367,"start":3368,"enrollment":563,"conditions":3369,"interventions":3370},"NCT02804373","Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome",[90,91],"2019-01","2019-06-18","2014-06",[21],[3352,3371],"Oxytocin",{"trials":3373,"activeCount":101},[],{"trials":3375,"activeCount":101},[],{"intervention":3377,"totalTrials":97,"cells":3378},"Dupilumab Prefilled Syringe",{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3396,"NA":3398},{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"trials":3384,"activeCount":101},[],{"trials":3386,"activeCount":101},[3387],{"nctId":3388,"briefTitle":3389,"status":2584,"phases":3390,"primaryCompletion":1419,"completion":1419,"start":3391,"enrollment":3392,"conditions":3393,"interventions":3395},"NCT04244006","A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome",[90,91],"2020-07-23",24,[3394],"Netherton Syndrome",[3377],{"trials":3397,"activeCount":101},[],{"trials":3399,"activeCount":101},[],{"intervention":1086,"totalTrials":97,"cells":3401},{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3406,"PHASE3":3408,"PHASE4":3414,"NA":3416},{"trials":3403,"activeCount":101},[],{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"trials":3409,"activeCount":101},[3410],{"nctId":1075,"briefTitle":1076,"status":1077,"phases":3411,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":3412,"interventions":3413},[91],[1083],[1085,1086,1087,1064],{"trials":3415,"activeCount":101},[],{"trials":3417,"activeCount":101},[],{"intervention":1087,"totalTrials":97,"cells":3419},{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3426,"PHASE4":3432,"NA":3434},{"trials":3421,"activeCount":101},[],{"trials":3423,"activeCount":101},[],{"trials":3425,"activeCount":101},[],{"trials":3427,"activeCount":101},[3428],{"nctId":1075,"briefTitle":1076,"status":1077,"phases":3429,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":3430,"interventions":3431},[91],[1083],[1085,1086,1087,1064],{"trials":3433,"activeCount":101},[],{"trials":3435,"activeCount":101},[],{"intervention":3437,"totalTrials":97,"cells":3438},"Balloon catheter + oral misoprostol",{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3445,"PHASE4":3458,"NA":3460},{"trials":3440,"activeCount":101},[],{"trials":3442,"activeCount":101},[],{"trials":3444,"activeCount":101},[],{"trials":3446,"activeCount":101},[3447],{"nctId":3448,"briefTitle":3449,"status":1077,"phases":3450,"primaryCompletion":3451,"completion":3451,"start":3452,"enrollment":3453,"conditions":3454,"interventions":3456},"NCT03435458","Balloon to Induce Labor in Generous Women.",[91],"2023-02-02","2020-06-26",429,[3455],"Maternal Obesity",[3437,3457],"Oral misoprostol alone",{"trials":3459,"activeCount":101},[],{"trials":3461,"activeCount":101},[],{"intervention":3457,"totalTrials":97,"cells":3463},{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3470,"PHASE4":3476,"NA":3478},{"trials":3465,"activeCount":101},[],{"trials":3467,"activeCount":101},[],{"trials":3469,"activeCount":101},[],{"trials":3471,"activeCount":101},[3472],{"nctId":3448,"briefTitle":3449,"status":1077,"phases":3473,"primaryCompletion":3451,"completion":3451,"start":3452,"enrollment":3453,"conditions":3474,"interventions":3475},[91],[3455],[3437,3457],{"trials":3477,"activeCount":101},[],{"trials":3479,"activeCount":101},[],{"intervention":3481,"totalTrials":253,"cells":3482},"propranolol",{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3487,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3484,"activeCount":101},[],{"trials":3486,"activeCount":101},[],{"trials":3488,"activeCount":101},[3489,3498],{"nctId":3490,"briefTitle":3491,"status":264,"phases":3492,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":840,"conditions":3495,"interventions":3497},"NCT00465608","Propranolol in Post Traumatic Stress Disorder",[90],"2008-11","2007-04",[3496],"Post-Traumatic Stress Disorder",[3481],{"nctId":3499,"briefTitle":3500,"status":264,"phases":3501,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":1653,"conditions":3505,"interventions":3507},"NCT01713556","Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial",[90],"2017-05","2017-06-30","2012-11",[3506],"Post-traumatic Stress Disorder",[3508],"Propranolol",{"trials":3510,"activeCount":101},[],{"trials":3512,"activeCount":101},[],{"trials":3514,"activeCount":101},[],{"intervention":3516,"totalTrials":253,"cells":3517},"Mesenchymal stem cells",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3522,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3519,"activeCount":101},[],{"trials":3521,"activeCount":101},[],{"trials":3523,"activeCount":101},[3524,3533],{"nctId":3525,"briefTitle":3526,"status":264,"phases":3527,"primaryCompletion":2671,"completion":2288,"start":3528,"enrollment":864,"conditions":3529,"interventions":3532},"NCT01076920","Mesenchymal Stem Cells and Myocardial Ischemia",[89,90],"2009-10",[3530,3531],"Chronic Myocardial Ischemia","Left Ventricular Dysfunction",[3516],{"nctId":3534,"briefTitle":3535,"status":1077,"phases":3536,"primaryCompletion":1737,"completion":1737,"start":3537,"enrollment":97,"conditions":3538,"interventions":3539},"NCT02403947","MEsenchymal StEm Cells for Multiple Sclerosis",[89,90],"2015-02",[2157],[3516,3540],"Suspension media",{"trials":3542,"activeCount":101},[],{"trials":3544,"activeCount":101},[],{"trials":3546,"activeCount":101},[],{"intervention":2592,"totalTrials":253,"cells":3548},{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3563,"PHASE4":3565,"NA":3567},{"trials":3550,"activeCount":101},[],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[3555,3559],{"nctId":2582,"briefTitle":2583,"status":2584,"phases":3556,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":2589,"conditions":3557,"interventions":3558},[90],[24],[2592,2573,1085,2593],{"nctId":2595,"briefTitle":2596,"status":1077,"phases":3560,"primaryCompletion":2598,"completion":2599,"start":2600,"enrollment":2601,"conditions":3561,"interventions":3562},[90],[24],[2592,2573,1085],{"trials":3564,"activeCount":101},[],{"trials":3566,"activeCount":101},[],{"trials":3568,"activeCount":101},[],{"intervention":3570,"totalTrials":97,"cells":3571},"Gene Therapy product CYL-02",{"EARLY_PHASE1":3572,"PHASE1":3574,"PHASE2":3576,"PHASE3":3589,"PHASE4":3591,"NA":3593},{"trials":3573,"activeCount":101},[],{"trials":3575,"activeCount":101},[],{"trials":3577,"activeCount":101},[3578],{"nctId":3579,"briefTitle":3580,"status":264,"phases":3581,"primaryCompletion":3582,"completion":3582,"start":3583,"enrollment":3584,"conditions":3585,"interventions":3587},"NCT02806687","Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer",[90],"2022-06-30","2017-01-30",68,[3586],"Pancreatic Adenocarcinoma",[3570,3588],"Gemcitabine",{"trials":3590,"activeCount":101},[],{"trials":3592,"activeCount":101},[],{"trials":3594,"activeCount":101},[],{"intervention":3588,"totalTrials":97,"cells":3596},{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3598,"activeCount":101},[],{"trials":3600,"activeCount":101},[],{"trials":3602,"activeCount":101},[3603],{"nctId":3579,"briefTitle":3580,"status":264,"phases":3604,"primaryCompletion":3582,"completion":3582,"start":3583,"enrollment":3584,"conditions":3605,"interventions":3606},[90],[3586],[3570,3588],{"trials":3608,"activeCount":101},[],{"trials":3610,"activeCount":101},[],{"trials":3612,"activeCount":101},[],{"intervention":3614,"totalTrials":97,"cells":3615},"Ketamine",{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3617,"activeCount":101},[],{"trials":3619,"activeCount":101},[],{"trials":3621,"activeCount":101},[3622],{"nctId":3623,"briefTitle":3624,"status":264,"phases":3625,"primaryCompletion":2111,"completion":3626,"start":1956,"enrollment":1123,"conditions":3627,"interventions":3629},"NCT00961194","Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain",[90],"2014-03",[3628],"Neuropathic Pain",[3614],{"trials":3631,"activeCount":101},[],{"trials":3633,"activeCount":101},[],{"trials":3635,"activeCount":101},[],{"intervention":3637,"totalTrials":97,"cells":3638},"Bortezomib",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3654,"PHASE4":3656,"NA":3658},{"trials":3640,"activeCount":101},[],{"trials":3642,"activeCount":101},[],{"trials":3644,"activeCount":101},[3645],{"nctId":3646,"briefTitle":3647,"status":264,"phases":3648,"primaryCompletion":3649,"completion":3650,"start":3651,"enrollment":1060,"conditions":3652,"interventions":3653},"NCT00642395","Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)",[90],"2008-10","2011-07","2007-07",[24],[3637],{"trials":3655,"activeCount":101},[],{"trials":3657,"activeCount":101},[],{"trials":3659,"activeCount":101},[],{"intervention":3661,"totalTrials":97,"cells":3662},"VX-745",{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3679,"PHASE4":3681,"NA":3683},{"trials":3664,"activeCount":101},[],{"trials":3666,"activeCount":101},[],{"trials":3668,"activeCount":101},[3669],{"nctId":3670,"briefTitle":3671,"status":264,"phases":3672,"primaryCompletion":3673,"completion":3674,"start":3675,"enrollment":3676,"conditions":3677,"interventions":3678},"NCT03435861","Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients",[90],"2021-04-30","2021-06-30","2018-10-08",34,[29],[3661],{"trials":3680,"activeCount":101},[],{"trials":3682,"activeCount":101},[],{"trials":3684,"activeCount":101},[],{"intervention":3686,"totalTrials":97,"cells":3687},"Vildagliptin",{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3704,"PHASE4":3706,"NA":3708},{"trials":3689,"activeCount":101},[],{"trials":3691,"activeCount":101},[],{"trials":3693,"activeCount":101},[3694],{"nctId":3695,"briefTitle":3696,"status":264,"phases":3697,"primaryCompletion":3698,"completion":3699,"start":1703,"enrollment":3700,"conditions":3701,"interventions":3703},"NCT01452113","Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy",[90],"2013-01","2013-03",21,[3702],"Diabetes Mellitus",[3686],{"trials":3705,"activeCount":101},[],{"trials":3707,"activeCount":101},[],{"trials":3709,"activeCount":101},[],{"intervention":3711,"totalTrials":97,"cells":3712},"Syntocinon®\u002F- Spray",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[],{"trials":3718,"activeCount":101},[3719],{"nctId":3720,"briefTitle":3721,"status":264,"phases":3722,"primaryCompletion":3251,"completion":3251,"start":2155,"enrollment":3392,"conditions":3723,"interventions":3725},"NCT01038570","Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo",[90],[3724],"Prader Willi Syndrome",[3711,3726],"Physiological serum",{"trials":3728,"activeCount":101},[],{"trials":3730,"activeCount":101},[],{"trials":3732,"activeCount":101},[],{"intervention":3726,"totalTrials":97,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3745,"PHASE4":3747,"NA":3749},{"trials":3736,"activeCount":101},[],{"trials":3738,"activeCount":101},[],{"trials":3740,"activeCount":101},[3741],{"nctId":3720,"briefTitle":3721,"status":264,"phases":3742,"primaryCompletion":3251,"completion":3251,"start":2155,"enrollment":3392,"conditions":3743,"interventions":3744},[90],[3724],[3711,3726],{"trials":3746,"activeCount":101},[],{"trials":3748,"activeCount":101},[],{"trials":3750,"activeCount":101},[],{"intervention":3752,"totalTrials":97,"cells":3753},"Misoprostol",{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3755,"activeCount":101},[],{"trials":3757,"activeCount":101},[],{"trials":3759,"activeCount":101},[3760],{"nctId":3761,"briefTitle":3762,"status":264,"phases":3763,"primaryCompletion":2023,"completion":2023,"start":3764,"enrollment":3765,"conditions":3766,"interventions":3768},"NCT01765881","Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2",[90],"2012-09",1700,[3767],"Delivery Uterine",[3752,3769],"Dinoprostone",{"trials":3771,"activeCount":101},[],{"trials":3773,"activeCount":101},[],{"trials":3775,"activeCount":101},[],{"intervention":3769,"totalTrials":97,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3779,"activeCount":101},[],{"trials":3781,"activeCount":101},[],{"trials":3783,"activeCount":101},[3784],{"nctId":3761,"briefTitle":3762,"status":264,"phases":3785,"primaryCompletion":2023,"completion":2023,"start":3764,"enrollment":3765,"conditions":3786,"interventions":3787},[90],[3767],[3752,3769],{"trials":3789,"activeCount":101},[],{"trials":3791,"activeCount":101},[],{"trials":3793,"activeCount":101},[],{"intervention":3795,"totalTrials":97,"cells":3796},"ioflupane 123I",{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3798,"activeCount":101},[],{"trials":3800,"activeCount":101},[],{"trials":3802,"activeCount":101},[3803],{"nctId":3804,"briefTitle":3805,"status":264,"phases":3806,"primaryCompletion":3807,"completion":3808,"start":1956,"enrollment":840,"conditions":3809,"interventions":3810},"NCT00940914","Dopaminergic Loss and Pain in Parkinson's Disease",[90],"2010-03","2010-07",[2457,32],[3795],{"trials":3812,"activeCount":101},[],{"trials":3814,"activeCount":101},[],{"trials":3816,"activeCount":101},[],{"intervention":3818,"totalTrials":97,"cells":3819},"Autologous ASC",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3834,"PHASE4":3836,"NA":3838},{"trials":3821,"activeCount":101},[],{"trials":3823,"activeCount":101},[],{"trials":3825,"activeCount":101},[3826],{"nctId":3827,"briefTitle":3828,"status":1077,"phases":3829,"primaryCompletion":3830,"completion":3830,"start":1014,"enrollment":253,"conditions":3831,"interventions":3833},"NCT03968198","Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia.",[90],"2023-03-10",[3832],"Critical Limb Ischemia and Peripheral Artery Disease",[3818],{"trials":3835,"activeCount":101},[],{"trials":3837,"activeCount":101},[],{"trials":3839,"activeCount":101},[],{"intervention":3841,"totalTrials":97,"cells":3842},"Autologous MSC from bone marrow",{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3844,"activeCount":101},[],{"trials":3846,"activeCount":101},[],{"trials":3848,"activeCount":101},[3849],{"nctId":3850,"briefTitle":3851,"status":264,"phases":3852,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":2661,"conditions":3855,"interventions":3856},"NCT02462330","Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)",[90],"2022-12-19","2016-02-19",[3530],[3841],{"trials":3858,"activeCount":101},[],{"trials":3860,"activeCount":101},[],{"trials":3862,"activeCount":101},[],{"intervention":3864,"totalTrials":97,"cells":3865},"Eltrombopag",{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3870,"PHASE3":3882,"PHASE4":3884,"NA":3886},{"trials":3867,"activeCount":101},[],{"trials":3869,"activeCount":101},[],{"trials":3871,"activeCount":101},[3872],{"nctId":3873,"briefTitle":3874,"status":264,"phases":3875,"primaryCompletion":3876,"completion":3876,"start":3877,"enrollment":3878,"conditions":3879,"interventions":3881},"NCT03638817","Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia",[90],"2023-06-27","2019-08-02",13,[3880],"Thrombocytopenia",[3864],{"trials":3883,"activeCount":101},[],{"trials":3885,"activeCount":101},[],{"trials":3887,"activeCount":101},[],{"intervention":3889,"totalTrials":97,"cells":3890},"Carfilzomib\u002FLenalidomide\u002FDexamethasone",{"EARLY_PHASE1":3891,"PHASE1":3893,"PHASE2":3895,"PHASE3":3904,"PHASE4":3906,"NA":3908},{"trials":3892,"activeCount":101},[],{"trials":3894,"activeCount":101},[],{"trials":3896,"activeCount":101},[3897],{"nctId":3898,"briefTitle":3899,"status":264,"phases":3900,"primaryCompletion":3901,"completion":3901,"start":2671,"enrollment":2601,"conditions":3902,"interventions":3903},"NCT02405364","Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction",[90],"2019-11-25",[24],[3889],{"trials":3905,"activeCount":101},[],{"trials":3907,"activeCount":101},[],{"trials":3909,"activeCount":101},[],{"intervention":3911,"totalTrials":97,"cells":3912},"Expanded autologous ASCs",{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3917,"PHASE3":3927,"PHASE4":3929,"NA":3931},{"trials":3914,"activeCount":101},[],{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[3919],{"nctId":3920,"briefTitle":3921,"status":264,"phases":3922,"primaryCompletion":3923,"completion":3923,"start":2432,"enrollment":3878,"conditions":3924,"interventions":3926},"NCT01211028","Adipose CELL Derived Regenerative Endothelial Angiogenic Medicine",[89,90],"2012-07",[3925,1379],"Peripheral Vascular Diseases",[3911],{"trials":3928,"activeCount":101},[],{"trials":3930,"activeCount":101},[],{"trials":3932,"activeCount":101},[],{"intervention":3934,"totalTrials":97,"cells":3935},"phenylephrine",{"EARLY_PHASE1":3936,"PHASE1":3938,"PHASE2":3940,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3937,"activeCount":101},[],{"trials":3939,"activeCount":101},[],{"trials":3941,"activeCount":101},[3942],{"nctId":3943,"briefTitle":3944,"status":264,"phases":3945,"primaryCompletion":2431,"completion":2111,"start":2154,"enrollment":3946,"conditions":3947,"interventions":3949},"NCT01533662","Prophylactic Phenylephrine Infusion for Preventing Hypotension During Spinal Anesthesia",[90],64,[3948],"Orthopedic Surgery of Lower Limb",[3934,3950],"patients receiving saline",{"trials":3952,"activeCount":101},[],{"trials":3954,"activeCount":101},[],{"trials":3956,"activeCount":101},[],{"intervention":3950,"totalTrials":97,"cells":3958},{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3963,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3960,"activeCount":101},[],{"trials":3962,"activeCount":101},[],{"trials":3964,"activeCount":101},[3965],{"nctId":3943,"briefTitle":3944,"status":264,"phases":3966,"primaryCompletion":2431,"completion":2111,"start":2154,"enrollment":3946,"conditions":3967,"interventions":3968},[90],[3948],[3934,3950],{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"trials":3974,"activeCount":101},[],{"intervention":3976,"totalTrials":97,"cells":3977},"Tocilizumab",{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3982,"PHASE3":3995,"PHASE4":3997,"NA":3999},{"trials":3979,"activeCount":101},[],{"trials":3981,"activeCount":101},[],{"trials":3983,"activeCount":101},[3984],{"nctId":3985,"briefTitle":3986,"status":264,"phases":3987,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":3990,"conditions":3991,"interventions":3994},"NCT04779957","Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy",[90],"2024-08-09","2021-10-01",18,[3992,3993],"Kidney Transplantation","Graft Failure",[3976],{"trials":3996,"activeCount":101},[],{"trials":3998,"activeCount":101},[],{"trials":4000,"activeCount":101},[],{"intervention":4002,"totalTrials":97,"cells":4003},"Dupilumab",{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4021,"PHASE4":4023,"NA":4025},{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[4010],{"nctId":4011,"briefTitle":4012,"status":264,"phases":4013,"primaryCompletion":4014,"completion":4015,"start":4016,"enrollment":4017,"conditions":4018,"interventions":4020},"NCT03861455","Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids",[90],"2023-11-09","2023-12-20","2019-07-15",94,[4019],"Chronic Hand Eczema",[4002],{"trials":4022,"activeCount":101},[],{"trials":4024,"activeCount":101},[],{"trials":4026,"activeCount":101},[],{"intervention":4028,"totalTrials":97,"cells":4029},"Amantadine",{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4031,"activeCount":101},[],{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[4036],{"nctId":4037,"briefTitle":4038,"status":264,"phases":4039,"primaryCompletion":4040,"completion":4041,"start":4042,"enrollment":4043,"conditions":4044,"interventions":4045},"NCT01538329","Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease",[90],"2018-02-20","2019-02-26","2012-03-04",210,[15],[4028],{"trials":4047,"activeCount":101},[],{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[],{"intervention":4053,"totalTrials":97,"cells":4054},"Lixisenatide",{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4070,"PHASE4":4072,"NA":4074},{"trials":4056,"activeCount":101},[],{"trials":4058,"activeCount":101},[],{"trials":4060,"activeCount":101},[4061],{"nctId":4062,"briefTitle":4063,"status":264,"phases":4064,"primaryCompletion":4065,"completion":4065,"start":4066,"enrollment":4067,"conditions":4068,"interventions":4069},"NCT03439943","Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease",[90],"2021-04-15","2018-06-13",156,[15],[4053],{"trials":4071,"activeCount":101},[],{"trials":4073,"activeCount":101},[],{"trials":4075,"activeCount":101},[],{"intervention":4077,"totalTrials":97,"cells":4078},"Levovist",{"EARLY_PHASE1":4079,"PHASE1":4081,"PHASE2":4083,"PHASE3":4093,"PHASE4":4095,"NA":4097},{"trials":4080,"activeCount":101},[],{"trials":4082,"activeCount":101},[],{"trials":4084,"activeCount":101},[4085],{"nctId":4086,"briefTitle":4087,"status":1077,"phases":4088,"primaryCompletion":4089,"completion":4089,"start":4089,"enrollment":840,"conditions":4090,"interventions":4092},"NCT00222040","Microbubbles and Ultrasound in Stroke Trial: MUST Study",[90],"2004-06",[4091],"Acute Ischemic Stroke",[4077],{"trials":4094,"activeCount":101},[],{"trials":4096,"activeCount":101},[],{"trials":4098,"activeCount":101},[],{"intervention":2593,"totalTrials":97,"cells":4100},{"EARLY_PHASE1":4101,"PHASE1":4103,"PHASE2":4105,"PHASE3":4111,"PHASE4":4113,"NA":4115},{"trials":4102,"activeCount":101},[],{"trials":4104,"activeCount":101},[],{"trials":4106,"activeCount":101},[4107],{"nctId":2582,"briefTitle":2583,"status":2584,"phases":4108,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":2589,"conditions":4109,"interventions":4110},[90],[24],[2592,2573,1085,2593],{"trials":4112,"activeCount":101},[],{"trials":4114,"activeCount":101},[],{"trials":4116,"activeCount":101},[],{"intervention":3540,"totalTrials":97,"cells":4118},{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4129,"PHASE4":4131,"NA":4133},{"trials":4120,"activeCount":101},[],{"trials":4122,"activeCount":101},[],{"trials":4124,"activeCount":101},[4125],{"nctId":3534,"briefTitle":3535,"status":1077,"phases":4126,"primaryCompletion":1737,"completion":1737,"start":3537,"enrollment":97,"conditions":4127,"interventions":4128},[89,90],[2157],[3516,3540],{"trials":4130,"activeCount":101},[],{"trials":4132,"activeCount":101},[],{"trials":4134,"activeCount":101},[],{"intervention":4136,"totalTrials":97,"cells":4137},"anticoagulation of the dialysis circuit",{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4154,"PHASE4":4156,"NA":4158},{"trials":4139,"activeCount":101},[],{"trials":4141,"activeCount":101},[],{"trials":4143,"activeCount":101},[4144],{"nctId":4145,"briefTitle":4146,"status":264,"phases":4147,"primaryCompletion":928,"completion":928,"start":4148,"enrollment":4149,"conditions":4150,"interventions":4153},"NCT03842657","Regional Anticoagulation of Dialysis Circuits With a Calcium-free Citrate-containing Dialysate",[90],"2019-07-05",97,[4151,4152],"Hemodialysis Complication","Bleeding",[4136],{"trials":4155,"activeCount":101},[],{"trials":4157,"activeCount":101},[],{"trials":4159,"activeCount":101},[],{"intervention":4161,"totalTrials":97,"cells":4162},"nicotinic acid",{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4164,"activeCount":101},[],{"trials":4166,"activeCount":101},[],{"trials":4168,"activeCount":101},[4169],{"nctId":4170,"briefTitle":4171,"status":264,"phases":4172,"primaryCompletion":3032,"completion":4173,"start":1704,"enrollment":3392,"conditions":4174,"interventions":4175},"NCT01083329","Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects",[90],"2012-06",[18],[4161],{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"trials":4181,"activeCount":101},[],{"intervention":4183,"totalTrials":253,"cells":4184},"Apelin",{"EARLY_PHASE1":4185,"PHASE1":4187,"PHASE2":4206,"PHASE3":4208,"PHASE4":4210,"NA":4212},{"trials":4186,"activeCount":101},[],{"trials":4188,"activeCount":101},[4189,4196],{"nctId":4190,"briefTitle":4191,"status":264,"phases":4192,"primaryCompletion":2068,"completion":2068,"start":2221,"enrollment":19,"conditions":4193,"interventions":4195},"NCT02033473","Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers",[89],[4194],"Healthy",[4183],{"nctId":4197,"briefTitle":4198,"status":264,"phases":4199,"primaryCompletion":4200,"completion":4200,"start":4201,"enrollment":572,"conditions":4202,"interventions":4204},"NCT02724566","Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers",[89],"2017-04","2016-05",[4203],"Diabetes",[4205],"apelin",{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[],{"trials":4211,"activeCount":101},[],{"trials":4213,"activeCount":101},[],{"intervention":4215,"totalTrials":97,"cells":4216},"Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes",{"EARLY_PHASE1":4217,"PHASE1":4219,"PHASE2":4227,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4218,"activeCount":101},[],{"trials":4220,"activeCount":101},[4221],{"nctId":4222,"briefTitle":4223,"status":264,"phases":4224,"primaryCompletion":3699,"completion":3699,"start":1662,"enrollment":1123,"conditions":4225,"interventions":4226},"NCT01274455","Gene Therapy of Pancreatic Ductal Adenocarcinoma",[89],[3586],[4215],{"trials":4228,"activeCount":101},[],{"trials":4230,"activeCount":101},[],{"trials":4232,"activeCount":101},[],{"trials":4234,"activeCount":101},[],{"intervention":4236,"totalTrials":97,"cells":4237},"Autologous mesenchymal stem cells",{"EARLY_PHASE1":4238,"PHASE1":4240,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4239,"activeCount":101},[],{"trials":4241,"activeCount":101},[4242],{"nctId":4243,"briefTitle":4244,"status":2968,"phases":4245,"primaryCompletion":4246,"completion":4246,"start":2752,"enrollment":101,"conditions":4247,"interventions":4248},"NCT02460770","Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device",[89],"2017-06",[3530],[4236],{"trials":4250,"activeCount":101},[],{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":101},[],{"trials":4256,"activeCount":101},[],{"intervention":4258,"totalTrials":97,"cells":4259},"Botulism Toxin Treatment",{"EARLY_PHASE1":4260,"PHASE1":4262,"PHASE2":4273,"PHASE3":4275,"PHASE4":4277,"NA":4279},{"trials":4261,"activeCount":101},[],{"trials":4263,"activeCount":101},[4264],{"nctId":4265,"briefTitle":4266,"status":264,"phases":4267,"primaryCompletion":4268,"completion":4268,"start":2023,"enrollment":596,"conditions":4269,"interventions":4272},"NCT02782702","Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.",[89],"2017-11",[4270,4271],"Hailey-Hailey Disease","Darier Disease",[4258],{"trials":4274,"activeCount":101},[],{"trials":4276,"activeCount":101},[],{"trials":4278,"activeCount":101},[],{"trials":4280,"activeCount":101},[],{"intervention":4282,"totalTrials":97,"cells":4283},"PET with 18 F-Flutemetamol",{"EARLY_PHASE1":4284,"PHASE1":4296,"PHASE2":4298,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4285,"activeCount":101},[4286],{"nctId":4287,"briefTitle":4288,"status":1077,"phases":4289,"primaryCompletion":4290,"completion":4290,"start":4291,"enrollment":4292,"conditions":4293,"interventions":4295},"NCT03232632","Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.",[88],"2019-09-15","2017-03-15",7,[4294],"Cardiac Amyloidosis",[4282],{"trials":4297,"activeCount":101},[],{"trials":4299,"activeCount":101},[],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[],{"trials":4305,"activeCount":101},[],{"intervention":4307,"totalTrials":878,"cells":4308},"blood sample",{"EARLY_PHASE1":4309,"PHASE1":4311,"PHASE2":4313,"PHASE3":4315,"PHASE4":4317,"NA":4319},{"trials":4310,"activeCount":101},[],{"trials":4312,"activeCount":101},[],{"trials":4314,"activeCount":101},[],{"trials":4316,"activeCount":101},[],{"trials":4318,"activeCount":101},[],{"trials":4320,"activeCount":101},[4321,4330,4343,4354,4364,4374],{"nctId":4322,"briefTitle":4323,"status":264,"phases":4324,"primaryCompletion":4325,"completion":4325,"start":4326,"enrollment":709,"conditions":4327,"interventions":4329},"NCT04746053","Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)",[93],"2023-10-12","2021-04-12",[4328],"Genital Diseases, Female",[4307],{"nctId":4331,"briefTitle":4332,"status":264,"phases":4333,"primaryCompletion":4334,"completion":4334,"start":4335,"enrollment":333,"conditions":4336,"interventions":4338},"NCT05207020","Development and Validation of the Blood Glucose Measurement Device by Air Analysis Expired",[93],"2023-02-09","2021-12-01",[4337],"Diabetes Mellitus, Type 2",[4339,4340,4341,4342],"Veinous glycemia","Capillary glycemia","constitution biological collection","Blood sample",{"nctId":4344,"briefTitle":4345,"status":264,"phases":4346,"primaryCompletion":2842,"completion":4347,"start":4348,"enrollment":4349,"conditions":4350,"interventions":4352},"NCT02824159","Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib",[],"2020-12","2016-04",121,[4351],"Hematological Malignancies",[4353,4342],"Saliva samples",{"nctId":4355,"briefTitle":4356,"status":264,"phases":4357,"primaryCompletion":4358,"completion":4358,"start":4359,"enrollment":4360,"conditions":4361,"interventions":4362},"NCT02602587","Study of Dendrogenin A \u002F Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients",[93],"2018-11-20","2014-11-25",37,[639],[4342,4363],"Bone marrow sample",{"nctId":4365,"briefTitle":4366,"status":264,"phases":4367,"primaryCompletion":4268,"completion":4268,"start":3537,"enrollment":4368,"conditions":4369,"interventions":4371},"NCT02390232","Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH",[],176,[4370],"Non-alcoholic Fatty Liver Disease",[4372,4373,4307],"liver biopsy","collection of stools",{"nctId":4375,"briefTitle":4376,"status":264,"phases":4377,"primaryCompletion":2288,"completion":2288,"start":3251,"enrollment":4378,"conditions":4379,"interventions":4381},"NCT02583620","Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia",[93],553,[4380],"Myopia",[4307],{"intervention":3371,"totalTrials":970,"cells":4383},{"EARLY_PHASE1":4384,"PHASE1":4386,"PHASE2":4388,"PHASE3":4405,"PHASE4":4411,"NA":4413},{"trials":4385,"activeCount":101},[],{"trials":4387,"activeCount":101},[],{"trials":4389,"activeCount":101},[4390,4397],{"nctId":4391,"briefTitle":4392,"status":264,"phases":4393,"primaryCompletion":2672,"completion":4394,"start":3650,"enrollment":970,"conditions":4395,"interventions":4396},"NCT01548521","Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies",[89,90],"2012-04",[21],[3371],{"nctId":4398,"briefTitle":4399,"status":264,"phases":4400,"primaryCompletion":4401,"completion":4401,"start":2431,"enrollment":3990,"conditions":4402,"interventions":4403},"NCT02205034","Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants",[89,90],"2014-07",[3724],[4404],"oxytocin",{"trials":4406,"activeCount":101},[4407],{"nctId":3363,"briefTitle":3364,"status":264,"phases":4408,"primaryCompletion":3366,"completion":3367,"start":3368,"enrollment":563,"conditions":4409,"interventions":4410},[90,91],[21],[3352,3371],{"trials":4412,"activeCount":101},[],{"trials":4414,"activeCount":101},[4415,4423],{"nctId":4416,"briefTitle":4417,"status":264,"phases":4418,"primaryCompletion":4419,"completion":4420,"start":1617,"enrollment":3676,"conditions":4421,"interventions":4422},"NCT03081832","Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.",[93],"2018-05","2018-12",[21],[3371],{"nctId":4424,"briefTitle":4425,"status":264,"phases":4426,"primaryCompletion":3366,"completion":4427,"start":4428,"enrollment":1846,"conditions":4429,"interventions":4430},"NCT03114371","Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years",[93],"2019-01-11","2016-11-28",[21],[3371,3371],{"intervention":996,"totalTrials":253,"cells":4432},{"EARLY_PHASE1":4433,"PHASE1":4435,"PHASE2":4437,"PHASE3":4439,"PHASE4":4441,"NA":4443},{"trials":4434,"activeCount":101},[],{"trials":4436,"activeCount":101},[],{"trials":4438,"activeCount":101},[],{"trials":4440,"activeCount":101},[],{"trials":4442,"activeCount":101},[],{"trials":4444,"activeCount":101},[4445,4449],{"nctId":987,"briefTitle":988,"status":264,"phases":4446,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":4447,"interventions":4448},[],[35],[972,996],{"nctId":1009,"briefTitle":1010,"status":264,"phases":4450,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":4451,"interventions":4452},[93],[35],[972,996],{"intervention":2847,"totalTrials":253,"cells":4454},{"EARLY_PHASE1":4455,"PHASE1":4457,"PHASE2":4459,"PHASE3":4461,"PHASE4":4467,"NA":4469},{"trials":4456,"activeCount":101},[],{"trials":4458,"activeCount":101},[],{"trials":4460,"activeCount":101},[],{"trials":4462,"activeCount":101},[4463],{"nctId":2839,"briefTitle":2840,"status":264,"phases":4464,"primaryCompletion":2842,"completion":2842,"start":2843,"enrollment":2844,"conditions":4465,"interventions":4466},[90,91],[15],[2828,2847,2848,2849],{"trials":4468,"activeCount":101},[],{"trials":4470,"activeCount":101},[4471],{"nctId":4472,"briefTitle":4473,"status":264,"phases":4474,"primaryCompletion":1895,"completion":4475,"start":4476,"enrollment":686,"conditions":4477,"interventions":4479},"NCT01044992","Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study",[93],"2006-05","2002-05",[4478],"Multisystemic Atrophy",[2847],{"intervention":4481,"totalTrials":97,"cells":4482},"Blood Test",{"EARLY_PHASE1":4483,"PHASE1":4485,"PHASE2":4487,"PHASE3":4489,"PHASE4":4491,"NA":4493},{"trials":4484,"activeCount":101},[],{"trials":4486,"activeCount":101},[],{"trials":4488,"activeCount":101},[],{"trials":4490,"activeCount":101},[],{"trials":4492,"activeCount":101},[],{"trials":4494,"activeCount":101},[4495],{"nctId":4496,"briefTitle":4497,"status":2584,"phases":4498,"primaryCompletion":4499,"completion":4499,"start":4500,"enrollment":563,"conditions":4501,"interventions":4503},"NCT03457038","Use of Fc-MBL to Detect and Monitor the Presence of PAMPs During Septic Shock",[93],"2019-07-18","2018-10-18",[4502],"Septic Shock",[4481],{"intervention":4505,"totalTrials":97,"cells":4506},"patient CSF extraction with hydrocephalus",{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4511,"PHASE3":4513,"PHASE4":4515,"NA":4517},{"trials":4508,"activeCount":101},[],{"trials":4510,"activeCount":101},[],{"trials":4512,"activeCount":101},[],{"trials":4514,"activeCount":101},[],{"trials":4516,"activeCount":101},[],{"trials":4518,"activeCount":101},[4519],{"nctId":4520,"briefTitle":4521,"status":264,"phases":4522,"primaryCompletion":2023,"completion":1760,"start":3699,"enrollment":663,"conditions":4523,"interventions":4525},"NCT02016352","Cerebrospinal Fluid Proteome in Hydrocephalus",[93],[4524],"Normal Pressure Hydrocephalus",[4505,4526],"witness CSF extraction",{"intervention":4526,"totalTrials":97,"cells":4528},{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4533,"PHASE3":4535,"PHASE4":4537,"NA":4539},{"trials":4530,"activeCount":101},[],{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"trials":4540,"activeCount":101},[4541],{"nctId":4520,"briefTitle":4521,"status":264,"phases":4542,"primaryCompletion":2023,"completion":1760,"start":3699,"enrollment":663,"conditions":4543,"interventions":4544},[93],[4524],[4505,4526],{"intervention":4546,"totalTrials":97,"cells":4547},"Blood Plasmacytoid dendritic cells (pDCs) absolute number",{"EARLY_PHASE1":4548,"PHASE1":4550,"PHASE2":4552,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4549,"activeCount":101},[],{"trials":4551,"activeCount":101},[],{"trials":4553,"activeCount":101},[],{"trials":4555,"activeCount":101},[],{"trials":4557,"activeCount":101},[],{"trials":4559,"activeCount":101},[4560],{"nctId":4561,"briefTitle":4562,"status":1077,"phases":4563,"primaryCompletion":2588,"completion":2588,"start":4564,"enrollment":4565,"conditions":4566,"interventions":4568},"NCT02956980","Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells. PLASMACYTOKID",[93],"2017-06-21",78,[4567],"Innate Immune Responses",[4546],{"intervention":4570,"totalTrials":97,"cells":4571},"non-drug intervention type",{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4576,"PHASE3":4578,"PHASE4":4580,"NA":4582},{"trials":4573,"activeCount":101},[],{"trials":4575,"activeCount":101},[],{"trials":4577,"activeCount":101},[],{"trials":4579,"activeCount":101},[],{"trials":4581,"activeCount":101},[],{"trials":4583,"activeCount":101},[4584],{"nctId":4585,"briefTitle":4586,"status":264,"phases":4587,"primaryCompletion":4588,"completion":4588,"start":4589,"enrollment":4590,"conditions":4591,"interventions":4593},"NCT03667092","Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor",[93],"2024-05-22","2018-09-01",47,[4592],"Midgut Neuroendocrine Tumors",[4570],{"intervention":4595,"totalTrials":97,"cells":4596},"patient treated with DMARD",{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4603,"PHASE4":4605,"NA":4607},{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":101},[],{"trials":4602,"activeCount":101},[],{"trials":4604,"activeCount":101},[],{"trials":4606,"activeCount":101},[],{"trials":4608,"activeCount":101},[4609],{"nctId":4610,"briefTitle":4611,"status":2584,"phases":4612,"primaryCompletion":4613,"completion":4613,"start":4358,"enrollment":4614,"conditions":4615,"interventions":4616},"NCT03980639","Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase",[],"2019-06-28",594226,[931],[4595],{"intervention":4618,"totalTrials":97,"cells":4619},"Rituximab (MABTHERA® or RITUXAN®).",{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4621,"activeCount":101},[],{"trials":4623,"activeCount":101},[],{"trials":4625,"activeCount":101},[],{"trials":4627,"activeCount":101},[],{"trials":4629,"activeCount":101},[],{"trials":4631,"activeCount":101},[4632],{"nctId":4633,"briefTitle":4634,"status":264,"phases":4635,"primaryCompletion":4636,"completion":4636,"start":2155,"enrollment":4637,"conditions":4638,"interventions":4644},"NCT00960713","The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders",[],"2012-01",35,[4639,4640,4641,4642,4643],"Pemphigus","Auto-immune Thrombocytopenic Purpura","Hemolytic Auto-immune Anaemia","Cold Agglutinin Disease","Cryoglobulinemia",[4618],{"intervention":4646,"totalTrials":97,"cells":4647},"acylated and unacylated ghrelin dosages",{"EARLY_PHASE1":4648,"PHASE1":4650,"PHASE2":4652,"PHASE3":4654,"PHASE4":4656,"NA":4658},{"trials":4649,"activeCount":101},[],{"trials":4651,"activeCount":101},[],{"trials":4653,"activeCount":101},[],{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[],{"trials":4659,"activeCount":101},[4660],{"nctId":4661,"briefTitle":4662,"status":2584,"phases":4663,"primaryCompletion":4664,"completion":4664,"start":4665,"enrollment":1351,"conditions":4666,"interventions":4671},"NCT04768803","Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and\u002For Overweight, and\u002For Obesity",[],"2023-12-15","2021-06-10",[4667,4668,4669,4670,21],"Angelman Syndrome","Smith-Magenis Syndrome","X Fragile Syndrome","Epilepsy",[4646],{"intervention":4673,"totalTrials":97,"cells":4674},"blood, urine and semen sample",{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4679,"PHASE3":4681,"PHASE4":4683,"NA":4685},{"trials":4676,"activeCount":101},[],{"trials":4678,"activeCount":101},[],{"trials":4680,"activeCount":101},[],{"trials":4682,"activeCount":101},[],{"trials":4684,"activeCount":101},[],{"trials":4686,"activeCount":101},[4687],{"nctId":4688,"briefTitle":4689,"status":264,"phases":4690,"primaryCompletion":4691,"completion":4691,"start":4692,"enrollment":864,"conditions":4693,"interventions":4695},"NCT03612609","Pilot Study to Detect DENGUE Virus in Sperm",[93],"2019-08-07","2019-02-06",[4694],"Dengue",[4673],{"intervention":4697,"totalTrials":97,"cells":4698},"genotyping",{"EARLY_PHASE1":4699,"PHASE1":4701,"PHASE2":4703,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4700,"activeCount":101},[],{"trials":4702,"activeCount":101},[],{"trials":4704,"activeCount":101},[],{"trials":4706,"activeCount":101},[],{"trials":4708,"activeCount":101},[],{"trials":4710,"activeCount":101},[4711],{"nctId":4712,"briefTitle":4713,"status":2968,"phases":4714,"primaryCompletion":3342,"completion":1737,"start":4715,"enrollment":101,"conditions":4716,"interventions":4718},"NCT03554239","Impact of Genotyping P450 2C19 on Hospitalization Period",[93],"2016-12",[4717],"Infection",[4697],{"intervention":4720,"totalTrials":97,"cells":4721},"Elbasvir and Grazoprevir",{"EARLY_PHASE1":4722,"PHASE1":4724,"PHASE2":4726,"PHASE3":4728,"PHASE4":4730,"NA":4732},{"trials":4723,"activeCount":101},[],{"trials":4725,"activeCount":101},[],{"trials":4727,"activeCount":101},[],{"trials":4729,"activeCount":101},[],{"trials":4731,"activeCount":101},[],{"trials":4733,"activeCount":101},[4734],{"nctId":4735,"briefTitle":4736,"status":264,"phases":4737,"primaryCompletion":4738,"completion":4738,"start":4739,"enrollment":663,"conditions":4740,"interventions":4742},"NCT03145623","Retrospective Efficacy and Safety Study With Elbasvir\u002FGrazoprevir in HCV-infected Patients With Chronic Kidney Disease",[],"2017-12-31","2017-06-02",[4741,1448],"Hepatitis C",[4720],{"intervention":4744,"totalTrials":97,"cells":4745},"Samples",{"EARLY_PHASE1":4746,"PHASE1":4748,"PHASE2":4750,"PHASE3":4752,"PHASE4":4754,"NA":4756},{"trials":4747,"activeCount":101},[],{"trials":4749,"activeCount":101},[],{"trials":4751,"activeCount":101},[],{"trials":4753,"activeCount":101},[],{"trials":4755,"activeCount":101},[],{"trials":4757,"activeCount":101},[4758],{"nctId":4759,"briefTitle":4760,"status":2584,"phases":4761,"primaryCompletion":4762,"completion":4762,"start":4763,"enrollment":596,"conditions":4764,"interventions":4766},"NCT05629299","Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM",[93],"2024-11","2022-11",[4765],"Monkeypox",[4744],{"intervention":4768,"totalTrials":97,"cells":4769},"Drug consumption",{"EARLY_PHASE1":4770,"PHASE1":4772,"PHASE2":4774,"PHASE3":4776,"PHASE4":4778,"NA":4780},{"trials":4771,"activeCount":101},[],{"trials":4773,"activeCount":101},[],{"trials":4775,"activeCount":101},[],{"trials":4777,"activeCount":101},[],{"trials":4779,"activeCount":101},[],{"trials":4781,"activeCount":101},[4782],{"nctId":4783,"briefTitle":4784,"status":264,"phases":4785,"primaryCompletion":4786,"completion":4786,"start":4787,"enrollment":4788,"conditions":4789,"interventions":4793},"NCT03931226","Impact of Spa Treatments on the Consumption of Care in Children",[],"2022-12-31","2018-06-01",8372,[4790,4791,4792],"Respiratory Disease","Otorhinolaryngologic Diseases","Dermatologic Disease",[4768],{"intervention":4795,"totalTrials":97,"cells":4796},"serology testing profiles description",{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4801,"PHASE3":4803,"PHASE4":4805,"NA":4807},{"trials":4798,"activeCount":101},[],{"trials":4800,"activeCount":101},[],{"trials":4802,"activeCount":101},[],{"trials":4804,"activeCount":101},[],{"trials":4806,"activeCount":101},[],{"trials":4808,"activeCount":101},[4809],{"nctId":4810,"briefTitle":4811,"status":264,"phases":4812,"primaryCompletion":3582,"completion":3582,"start":4813,"enrollment":4292,"conditions":4814,"interventions":4817},"NCT04785157","Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium.",[],"2021-06-01",[4815,4816,3506],"Covid19","Delirium",[4795,4818],"immune response characterization",{"intervention":4818,"totalTrials":97,"cells":4820},{"EARLY_PHASE1":4821,"PHASE1":4823,"PHASE2":4825,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4822,"activeCount":101},[],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[],{"trials":4828,"activeCount":101},[],{"trials":4830,"activeCount":101},[],{"trials":4832,"activeCount":101},[4833],{"nctId":4810,"briefTitle":4811,"status":264,"phases":4834,"primaryCompletion":3582,"completion":3582,"start":4813,"enrollment":4292,"conditions":4835,"interventions":4836},[],[4815,4816,3506],[4795,4818],{"intervention":1127,"totalTrials":97,"cells":4838},{"EARLY_PHASE1":4839,"PHASE1":4841,"PHASE2":4843,"PHASE3":4845,"PHASE4":4847,"NA":4849},{"trials":4840,"activeCount":101},[],{"trials":4842,"activeCount":101},[],{"trials":4844,"activeCount":101},[],{"trials":4846,"activeCount":101},[],{"trials":4848,"activeCount":101},[],{"trials":4850,"activeCount":101},[4851],{"nctId":1118,"briefTitle":1119,"status":264,"phases":4852,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":4853,"interventions":4854},[93],[1125],[1103,1127,1128],{"intervention":1128,"totalTrials":97,"cells":4856},{"EARLY_PHASE1":4857,"PHASE1":4859,"PHASE2":4861,"PHASE3":4863,"PHASE4":4865,"NA":4867},{"trials":4858,"activeCount":101},[],{"trials":4860,"activeCount":101},[],{"trials":4862,"activeCount":101},[],{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":101},[],{"trials":4868,"activeCount":101},[4869],{"nctId":1118,"briefTitle":1119,"status":264,"phases":4870,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":4871,"interventions":4872},[93],[1125],[1103,1127,1128],{"intervention":4874,"totalTrials":97,"cells":4875},"Analgesic protocol",{"EARLY_PHASE1":4876,"PHASE1":4878,"PHASE2":4880,"PHASE3":4882,"PHASE4":4884,"NA":4886},{"trials":4877,"activeCount":101},[],{"trials":4879,"activeCount":101},[],{"trials":4881,"activeCount":101},[],{"trials":4883,"activeCount":101},[],{"trials":4885,"activeCount":101},[],{"trials":4887,"activeCount":101},[4888],{"nctId":4889,"briefTitle":4890,"status":264,"phases":4891,"primaryCompletion":4892,"completion":4892,"start":4893,"enrollment":4894,"conditions":4895,"interventions":4897},"NCT04892940","Use of Virtual Reality to Reduce Morphine Consumption in Adolescents Undergoing Scoliosis Surgery",[93],"2024-07-24","2022-02-21",101,[4896],"Scoliosis",[4874],{"intervention":4899,"totalTrials":97,"cells":4900},"Collection of biological samples",{"EARLY_PHASE1":4901,"PHASE1":4903,"PHASE2":4905,"PHASE3":4907,"PHASE4":4909,"NA":4911},{"trials":4902,"activeCount":101},[],{"trials":4904,"activeCount":101},[],{"trials":4906,"activeCount":101},[],{"trials":4908,"activeCount":101},[],{"trials":4910,"activeCount":101},[],{"trials":4912,"activeCount":101},[4913],{"nctId":4914,"briefTitle":4915,"status":264,"phases":4916,"primaryCompletion":4917,"completion":4917,"start":4918,"enrollment":663,"conditions":4919,"interventions":4920},"NCT06407128","Valvular Microbiota and Valvulopathy",[93],"2025-08-30","2024-01-09",[1244],[4899],{"intervention":4339,"totalTrials":97,"cells":4922},{"EARLY_PHASE1":4923,"PHASE1":4925,"PHASE2":4927,"PHASE3":4929,"PHASE4":4931,"NA":4933},{"trials":4924,"activeCount":101},[],{"trials":4926,"activeCount":101},[],{"trials":4928,"activeCount":101},[],{"trials":4930,"activeCount":101},[],{"trials":4932,"activeCount":101},[],{"trials":4934,"activeCount":101},[4935],{"nctId":4331,"briefTitle":4332,"status":264,"phases":4936,"primaryCompletion":4334,"completion":4334,"start":4335,"enrollment":333,"conditions":4937,"interventions":4938},[93],[4337],[4339,4340,4341,4342],{"intervention":4340,"totalTrials":97,"cells":4940},{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4945,"PHASE3":4947,"PHASE4":4949,"NA":4951},{"trials":4942,"activeCount":101},[],{"trials":4944,"activeCount":101},[],{"trials":4946,"activeCount":101},[],{"trials":4948,"activeCount":101},[],{"trials":4950,"activeCount":101},[],{"trials":4952,"activeCount":101},[4953],{"nctId":4331,"briefTitle":4332,"status":264,"phases":4954,"primaryCompletion":4334,"completion":4334,"start":4335,"enrollment":333,"conditions":4955,"interventions":4956},[93],[4337],[4339,4340,4341,4342],{"intervention":4341,"totalTrials":97,"cells":4958},{"EARLY_PHASE1":4959,"PHASE1":4961,"PHASE2":4963,"PHASE3":4965,"PHASE4":4967,"NA":4969},{"trials":4960,"activeCount":101},[],{"trials":4962,"activeCount":101},[],{"trials":4964,"activeCount":101},[],{"trials":4966,"activeCount":101},[],{"trials":4968,"activeCount":101},[],{"trials":4970,"activeCount":101},[4971],{"nctId":4331,"briefTitle":4332,"status":264,"phases":4972,"primaryCompletion":4334,"completion":4334,"start":4335,"enrollment":333,"conditions":4973,"interventions":4974},[93],[4337],[4339,4340,4341,4342],{"intervention":4976,"totalTrials":97,"cells":4977},"F-MISO",{"EARLY_PHASE1":4978,"PHASE1":4980,"PHASE2":4982,"PHASE3":4984,"PHASE4":4986,"NA":4988},{"trials":4979,"activeCount":101},[],{"trials":4981,"activeCount":101},[],{"trials":4983,"activeCount":101},[],{"trials":4985,"activeCount":101},[],{"trials":4987,"activeCount":101},[],{"trials":4989,"activeCount":101},[4990],{"nctId":4991,"briefTitle":4992,"status":1077,"phases":4993,"primaryCompletion":2843,"completion":4715,"start":2431,"enrollment":878,"conditions":4994,"interventions":4996},"NCT02841332","Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma",[93],[4995],"Glioblastoma",[4976,4997],"Bevacizumab",{"intervention":4997,"totalTrials":97,"cells":4999},{"EARLY_PHASE1":5000,"PHASE1":5002,"PHASE2":5004,"PHASE3":5006,"PHASE4":5008,"NA":5010},{"trials":5001,"activeCount":101},[],{"trials":5003,"activeCount":101},[],{"trials":5005,"activeCount":101},[],{"trials":5007,"activeCount":101},[],{"trials":5009,"activeCount":101},[],{"trials":5011,"activeCount":101},[5012],{"nctId":4991,"briefTitle":4992,"status":1077,"phases":5013,"primaryCompletion":2843,"completion":4715,"start":2431,"enrollment":878,"conditions":5014,"interventions":5015},[93],[4995],[4976,4997],{"intervention":5017,"totalTrials":97,"cells":5018},"Blood sample collection",{"EARLY_PHASE1":5019,"PHASE1":5021,"PHASE2":5023,"PHASE3":5025,"PHASE4":5027,"NA":5029},{"trials":5020,"activeCount":101},[],{"trials":5022,"activeCount":101},[],{"trials":5024,"activeCount":101},[],{"trials":5026,"activeCount":101},[],{"trials":5028,"activeCount":101},[],{"trials":5030,"activeCount":101},[5031],{"nctId":5032,"briefTitle":5033,"status":264,"phases":5034,"primaryCompletion":5035,"completion":5036,"start":5037,"enrollment":3676,"conditions":5038,"interventions":5040},"NCT04384835","Analysis of Sexual Bias in Type 2 Innate Lymphoid Cells (ILC2) in Asthmatic Patients",[],"2022-05-01","2023-04-12","2021-03-08",[5039],"Asthma",[5017,5017],{"intervention":4353,"totalTrials":97,"cells":5042},{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5049,"PHASE4":5051,"NA":5053},{"trials":5044,"activeCount":101},[],{"trials":5046,"activeCount":101},[],{"trials":5048,"activeCount":101},[],{"trials":5050,"activeCount":101},[],{"trials":5052,"activeCount":101},[],{"trials":5054,"activeCount":101},[5055],{"nctId":4344,"briefTitle":4345,"status":264,"phases":5056,"primaryCompletion":2842,"completion":4347,"start":4348,"enrollment":4349,"conditions":5057,"interventions":5058},[],[4351],[4353,4342],{"intervention":948,"totalTrials":97,"cells":5060},{"EARLY_PHASE1":5061,"PHASE1":5063,"PHASE2":5065,"PHASE3":5067,"PHASE4":5069,"NA":5071},{"trials":5062,"activeCount":101},[],{"trials":5064,"activeCount":101},[],{"trials":5066,"activeCount":101},[],{"trials":5068,"activeCount":101},[],{"trials":5070,"activeCount":101},[],{"trials":5072,"activeCount":101},[5073],{"nctId":937,"briefTitle":938,"status":264,"phases":5074,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":5075,"interventions":5076},[],[18,945,946],[877,948],{"intervention":5078,"totalTrials":97,"cells":5079},"Levodopa test",{"EARLY_PHASE1":5080,"PHASE1":5082,"PHASE2":5084,"PHASE3":5086,"PHASE4":5088,"NA":5090},{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":101},[],{"trials":5085,"activeCount":101},[],{"trials":5087,"activeCount":101},[],{"trials":5089,"activeCount":101},[],{"trials":5091,"activeCount":101},[5092],{"nctId":5093,"briefTitle":5094,"status":264,"phases":5095,"primaryCompletion":5096,"completion":5097,"start":5098,"enrollment":5099,"conditions":5100,"interventions":5102},"NCT01577992","Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy",[93],"2013-06-30","2013-11-30","2011-12-01",42,[5101,1655],"Pain Threshold",[5078],{"intervention":5104,"totalTrials":97,"cells":5105},"Dosage de l'h-FABP",{"EARLY_PHASE1":5106,"PHASE1":5108,"PHASE2":5110,"PHASE3":5112,"PHASE4":5114,"NA":5116},{"trials":5107,"activeCount":101},[],{"trials":5109,"activeCount":101},[],{"trials":5111,"activeCount":101},[],{"trials":5113,"activeCount":101},[],{"trials":5115,"activeCount":101},[],{"trials":5117,"activeCount":101},[5118],{"nctId":5119,"briefTitle":5120,"status":264,"phases":5121,"primaryCompletion":1650,"completion":5122,"start":3251,"enrollment":5123,"conditions":5124,"interventions":5126},"NCT01326507","Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism",[93],"2011-12",165,[5125],"Pulmonary Embolism",[5104],{"intervention":5128,"totalTrials":97,"cells":5129},"Osteoblast sample",{"EARLY_PHASE1":5130,"PHASE1":5132,"PHASE2":5134,"PHASE3":5136,"PHASE4":5138,"NA":5140},{"trials":5131,"activeCount":101},[],{"trials":5133,"activeCount":101},[],{"trials":5135,"activeCount":101},[],{"trials":5137,"activeCount":101},[],{"trials":5139,"activeCount":101},[],{"trials":5141,"activeCount":101},[5142],{"nctId":5143,"briefTitle":5144,"status":264,"phases":5145,"primaryCompletion":3923,"completion":3923,"start":3807,"enrollment":2589,"conditions":5146,"interventions":5147},"NCT02829476","Ghrelin Resistance in Adolescents With Idiopathic Scoliosis",[93],[4896],[5128],{"intervention":4363,"totalTrials":97,"cells":5149},{"EARLY_PHASE1":5150,"PHASE1":5152,"PHASE2":5154,"PHASE3":5156,"PHASE4":5158,"NA":5160},{"trials":5151,"activeCount":101},[],{"trials":5153,"activeCount":101},[],{"trials":5155,"activeCount":101},[],{"trials":5157,"activeCount":101},[],{"trials":5159,"activeCount":101},[],{"trials":5161,"activeCount":101},[5162],{"nctId":4355,"briefTitle":4356,"status":264,"phases":5163,"primaryCompletion":4358,"completion":4358,"start":4359,"enrollment":4360,"conditions":5164,"interventions":5165},[93],[639],[4342,4363],{"intervention":5167,"totalTrials":97,"cells":5168},"Medical treatment with Mifégyne® and MisoOne®",{"EARLY_PHASE1":5169,"PHASE1":5171,"PHASE2":5173,"PHASE3":5175,"PHASE4":5177,"NA":5179},{"trials":5170,"activeCount":101},[],{"trials":5172,"activeCount":101},[],{"trials":5174,"activeCount":101},[],{"trials":5176,"activeCount":101},[],{"trials":5178,"activeCount":101},[],{"trials":5180,"activeCount":101},[5181],{"nctId":5182,"briefTitle":5183,"status":264,"phases":5184,"primaryCompletion":5185,"completion":5185,"start":5186,"enrollment":1957,"conditions":5187,"interventions":5189},"NCT05049980","Patient Satisfaction With the Management of a Stopped Pregnancy in the First Trimester",[93],"2022-02-14","2021-11-01",[5188],"Pregnancy Loss, Early",[5167],{"intervention":5191,"totalTrials":97,"cells":5192},"blood sample collection for CTC and MDSC analysis",{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5199,"PHASE4":5201,"NA":5203},{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[],{"trials":5198,"activeCount":101},[],{"trials":5200,"activeCount":101},[],{"trials":5202,"activeCount":101},[],{"trials":5204,"activeCount":101},[5205],{"nctId":5206,"briefTitle":5207,"status":264,"phases":5208,"primaryCompletion":2906,"completion":5209,"start":5210,"enrollment":5211,"conditions":5212,"interventions":5213},"NCT02827344","PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer",[],"2021-12","2015-10-01",216,[1051],[5191],{"intervention":5215,"totalTrials":97,"cells":5216},"cerebrospinal fluid",{"EARLY_PHASE1":5217,"PHASE1":5219,"PHASE2":5221,"PHASE3":5223,"PHASE4":5225,"NA":5227},{"trials":5218,"activeCount":101},[],{"trials":5220,"activeCount":101},[],{"trials":5222,"activeCount":101},[],{"trials":5224,"activeCount":101},[],{"trials":5226,"activeCount":101},[],{"trials":5228,"activeCount":101},[5229],{"nctId":5230,"briefTitle":5231,"status":264,"phases":5232,"primaryCompletion":4246,"completion":1737,"start":1097,"enrollment":5233,"conditions":5234,"interventions":5235},"NCT02946710","P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid",[],120,[29],[5215],{"intervention":5237,"totalTrials":97,"cells":5238},"Sample",{"EARLY_PHASE1":5239,"PHASE1":5241,"PHASE2":5243,"PHASE3":5245,"PHASE4":5247,"NA":5249},{"trials":5240,"activeCount":101},[],{"trials":5242,"activeCount":101},[],{"trials":5244,"activeCount":101},[],{"trials":5246,"activeCount":101},[],{"trials":5248,"activeCount":101},[],{"trials":5250,"activeCount":101},[5251],{"nctId":5252,"briefTitle":5253,"status":2584,"phases":5254,"primaryCompletion":5255,"completion":5255,"start":5256,"enrollment":563,"conditions":5257,"interventions":5258},"NCT04584593","Pilot Study to Detect SARS-CoV-2 Virus in Sperm",[93],"2022-02","2020-10-02",[4815],[5237],{"intervention":5260,"totalTrials":97,"cells":5261},"O-(2[18F]FLUOROETHYL)-L-TYROSINE",{"EARLY_PHASE1":5262,"PHASE1":5264,"PHASE2":5266,"PHASE3":5268,"PHASE4":5270,"NA":5272},{"trials":5263,"activeCount":101},[],{"trials":5265,"activeCount":101},[],{"trials":5267,"activeCount":101},[],{"trials":5269,"activeCount":101},[],{"trials":5271,"activeCount":101},[],{"trials":5273,"activeCount":101},[5274],{"nctId":5275,"briefTitle":5276,"status":264,"phases":5277,"primaryCompletion":1097,"completion":1097,"start":3032,"enrollment":5278,"conditions":5279,"interventions":5281},"NCT02286531","Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma",[93],93,[5280],"Low Grade Glioma",[5260],{"intervention":4372,"totalTrials":97,"cells":5283},{"EARLY_PHASE1":5284,"PHASE1":5286,"PHASE2":5288,"PHASE3":5290,"PHASE4":5292,"NA":5294},{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[],{"trials":5289,"activeCount":101},[],{"trials":5291,"activeCount":101},[],{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[5296],{"nctId":4365,"briefTitle":4366,"status":264,"phases":5297,"primaryCompletion":4268,"completion":4268,"start":3537,"enrollment":4368,"conditions":5298,"interventions":5299},[],[4370],[4372,4373,4307],{"intervention":4373,"totalTrials":97,"cells":5301},{"EARLY_PHASE1":5302,"PHASE1":5304,"PHASE2":5306,"PHASE3":5308,"PHASE4":5310,"NA":5312},{"trials":5303,"activeCount":101},[],{"trials":5305,"activeCount":101},[],{"trials":5307,"activeCount":101},[],{"trials":5309,"activeCount":101},[],{"trials":5311,"activeCount":101},[],{"trials":5313,"activeCount":101},[5314],{"nctId":4365,"briefTitle":4366,"status":264,"phases":5315,"primaryCompletion":4268,"completion":4268,"start":3537,"enrollment":4368,"conditions":5316,"interventions":5317},[],[4370],[4372,4373,4307],{"intervention":5319,"totalTrials":97,"cells":5320},"genetic analysis",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5325,"PHASE3":5327,"PHASE4":5329,"NA":5331},{"trials":5322,"activeCount":101},[],{"trials":5324,"activeCount":101},[],{"trials":5326,"activeCount":101},[],{"trials":5328,"activeCount":101},[],{"trials":5330,"activeCount":101},[],{"trials":5332,"activeCount":101},[5333],{"nctId":5334,"briefTitle":5335,"status":264,"phases":5336,"primaryCompletion":2388,"completion":2388,"start":1956,"enrollment":608,"conditions":5337,"interventions":5339},"NCT02422732","Functional Imaging and Reading Deficit in Children With NF1",[93],[5338],"Neurofibromatosis Type 1",[5319],{"intervention":5341,"totalTrials":97,"cells":5342},"apomorphine",{"EARLY_PHASE1":5343,"PHASE1":5345,"PHASE2":5347,"PHASE3":5349,"PHASE4":5351,"NA":5353},{"trials":5344,"activeCount":101},[],{"trials":5346,"activeCount":101},[],{"trials":5348,"activeCount":101},[],{"trials":5350,"activeCount":101},[],{"trials":5352,"activeCount":101},[],{"trials":5354,"activeCount":101},[5355],{"nctId":5356,"briefTitle":5357,"status":264,"phases":5358,"primaryCompletion":1605,"completion":5359,"start":5360,"enrollment":19,"conditions":5361,"interventions":5362},"NCT00524914","Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study",[93],"2008-03","2007-09",[2457],[5341],{"intervention":5364,"totalTrials":97,"cells":5365},"RNAseq",{"EARLY_PHASE1":5366,"PHASE1":5368,"PHASE2":5370,"PHASE3":5372,"PHASE4":5374,"NA":5376},{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[],{"trials":5371,"activeCount":101},[],{"trials":5373,"activeCount":101},[],{"trials":5375,"activeCount":101},[],{"trials":5377,"activeCount":101},[5378],{"nctId":5379,"briefTitle":5380,"status":2584,"phases":5381,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":449,"conditions":5385,"interventions":5387},"NCT05934045","Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma",[],"2023-06-01","2025-12-31","2023-01-01",[5386],"ALK-Positive Anaplastic Large Cell Lymphoma",[5364]]